



US011951005B2

(12) **United States Patent**  
**Gross et al.**

(10) **Patent No.:** **US 11,951,005 B2**  
(45) **Date of Patent:** **\*Apr. 9, 2024**

- (54) **IMPLANT FOR HEART VALVE**
- (71) Applicant: **CARDIOVALVE LTD.**, Or Yehuda (IL)
- (72) Inventors: **Yossi Gross**, Moshav Mazor (IL); **Gil Hacoheh**, Ramat Gan (IL)
- (73) Assignee: **CARDIOVALVE LTD.**, Or Yehuda (IL)
- (\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.  
  
This patent is subject to a terminal disclaimer.

- (21) Appl. No.: **18/218,419**
- (22) Filed: **Jul. 5, 2023**

- (65) **Prior Publication Data**  
US 2023/0346550 A1 Nov. 2, 2023

- Related U.S. Application Data**
- (63) Continuation of application No. 17/982,897, filed on Nov. 8, 2022, now Pat. No. 11,864,995, which is a (Continued)

- (51) **Int. Cl.**  
*A61F 2/24* (2006.01)  
*A61B 17/122* (2006.01)  
(Continued)
- (52) **U.S. Cl.**  
CPC ..... *A61F 2/2418* (2013.01); *A61B 17/122* (2013.01); *A61F 2/2409* (2013.01);  
(Continued)
- (58) **Field of Classification Search**  
CPC .... A61F 2/2409; A61F 2/2436; A61F 2/2466;  
A61F 2/2445; A61F 2/2463  
See application file for complete search history.

(56) **References Cited**  
U.S. PATENT DOCUMENTS

3,874,388 A	4/1975	King et al.
4,222,126 A	9/1980	Boretos et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA	2822801	8/2006
CN	103974674	8/2014

(Continued)

OTHER PUBLICATIONS


An Office Action dated Nov. 23, 2012, which issued during the prosecution of U.S. Appl. No. 13/033,852.  
(Continued)

*Primary Examiner* — Suzette J Gherbi  
(74) *Attorney, Agent, or Firm* — Sughrue Mion, PLLC

(57) **ABSTRACT**

A heart valve repair system includes a delivery sheath and an implant that includes a frame including a braided structure of intertwining strands and having a surface configured to contact an upstream surface of a native heart valve. First and second gripping members are coupled to the frame, each including atrial and ventricular arms. The implant is disposed in the sheath in a delivery state in which the frame defines a wall fully surrounding a central longitudinal axis of the implant. The distal end of the wall defines a distal opening of the frame. The distal end of the wall is disposed proximally to the second end of the ventricular arm of each of the gripping members. The second end of each ventricular arm moves toward the axis of the implant more than the first end moves toward the axis. Other embodiments are also described.

**28 Claims, 13 Drawing Sheets**





**Related U.S. Application Data**

continuation of application No. 16/888,210, filed on May 29, 2020, now Pat. No. 11,517,436, which is a continuation of application No. 16/284,331, filed on Feb. 25, 2019, now Pat. No. 10,702,385, which is a continuation of application No. 15/197,069, filed on Jun. 29, 2016, now Pat. No. 10,226,341, which is a continuation of application No. 14/237,258, filed as application No. PCT/IL2012/000293 on Aug. 5, 2012, now Pat. No. 9,387,078, which is a continuation-in-part of application No. 13/412,814, filed on Mar. 6, 2012, now Pat. No. 8,852,272.

(60) Provisional application No. 61/588,892, filed on Jan. 20, 2012, provisional application No. 61/537,276, filed on Sep. 21, 2011, provisional application No. 61/555,160, filed on Nov. 3, 2011, provisional application No. 61/525,281, filed on Aug. 19, 2011, provisional application No. 61/515,372, filed on Aug. 5, 2011.

(51) **Int. Cl.**

*A61B 17/00* (2006.01)  
*A61F 2/848* (2013.01)

(52) **U.S. Cl.**

CPC ..... *A61F 2/2436* (2013.01); *A61F 2/2439* (2013.01); *A61F 2/2454* (2013.01); *A61F 2/246* (2013.01); *A61F 2/2466* (2013.01); *A61B 2017/00243* (2013.01); *A61F 2/2427* (2013.01); *A61F 2/2433* (2013.01); *A61F 2/2442* (2013.01); *A61F 2/2445* (2013.01); *A61F 2/2463* (2013.01); *A61F 2/848* (2013.01); *A61F 2210/0014* (2013.01); *A61F 2220/0008* (2013.01); *A61F 2220/0016* (2013.01); *A61F 2220/0025* (2013.01); *A61F 2220/0091* (2013.01); *A61F 2230/0006* (2013.01); *A61F 2230/0013* (2013.01); *A61F 2230/005* (2013.01); *A61F 2230/0054* (2013.01); *A61F 2230/0078* (2013.01); *A61F 2250/0015* (2013.01); *A61F 2250/006* (2013.01); *A61F 2250/0069* (2013.01); *A61F 2250/0071* (2013.01)

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,261,342 A 4/1981 Aranguren  
4,340,091 A 7/1982 Skelton et al.  
4,423,525 A 1/1984 Vallana et al.  
4,853,986 A 8/1989 Allen  
4,892,541 A 1/1990 Alonso  
4,972,494 A 11/1990 White et al.  
5,108,420 A 4/1992 Marks  
5,314,473 A 5/1994 Godin  
5,405,378 A 4/1995 Strecker  
5,443,500 A 8/1995 Sigwart  
5,607,444 A 3/1997 Lam  
5,607,470 A 3/1997 Milo  
5,647,857 A 7/1997 Anderson et al.  
5,702,397 A 12/1997 Goble et al.  
5,713,948 A 2/1998 Uflacker  
5,716,417 A 2/1998 Girard et al.  
5,741,297 A 4/1998 Simon  
5,765,682 A 6/1998 Bley et al.  
5,776,140 A 7/1998 Cottone  
5,868,777 A 2/1999 Lam  
5,873,906 A 2/1999 Lau et al.  
5,954,766 A 9/1999 Zadno-Azizi et al.  
5,957,949 A 9/1999 Leonhardt et al.

5,980,565 A 11/1999 Jayaraman  
6,010,530 A 1/2000 Goicoechea  
6,019,787 A 2/2000 Richard et al.  
6,042,607 A 3/2000 Williamson, IV  
6,074,417 A 6/2000 Peredo  
6,113,612 A 9/2000 Swanson et al.  
6,120,534 A 9/2000 Ruiz  
6,126,686 A 10/2000 Badylak et al.  
6,152,937 A 11/2000 Peterson et al.  
6,165,183 A 12/2000 Kuehn et al.  
6,165,210 A 12/2000 Lau et al.  
6,187,020 B1 2/2001 Zegdi et al.  
6,193,745 B1 2/2001 Fogarty et al.  
6,264,700 B1 7/2001 Kilcoyne et al.  
6,287,339 B1 9/2001 Vasquez et al.  
6,312,465 B1 11/2001 Griffin et al.  
6,332,893 B1 12/2001 Mortier et al.  
6,334,873 B1 1/2002 Lane et al.  
6,346,074 B1 2/2002 Roth  
6,350,278 B1 2/2002 Lenker et al.  
6,352,561 B1 3/2002 Leopold et al.  
6,391,036 B1 5/2002 Berg et al.  
6,402,780 B2 6/2002 Williamson, IV  
6,409,755 B1 6/2002 Vrba  
6,419,696 B1 7/2002 Ortiz et al.  
6,428,550 B1 8/2002 Vargas et al.  
6,440,164 B1 8/2002 Dimatteo et al.  
6,454,799 B1 9/2002 Schreck  
6,458,153 B1 10/2002 Bailey et al.  
6,511,491 B2 1/2003 Grudem et al.  
6,530,952 B2 3/2003 Vesely  
6,540,782 B1 4/2003 Snyders  
6,551,350 B1 4/2003 Thornton et al.  
6,558,396 B1 5/2003 Inoue  
6,558,418 B2 5/2003 Carpentier et al.  
6,569,196 B1 5/2003 Vesely  
6,582,464 B2 6/2003 Gabbay  
6,602,263 B1 8/2003 Swanson et al.  
6,616,675 B1 9/2003 Evard et al.  
6,629,534 B1 10/2003 St. Goar et al.  
6,652,556 B1 11/2003 VanTessel et al.  
6,669,724 B2 12/2003 Park et al.  
6,682,558 B2 1/2004 Tu et al.  
6,699,256 B1 3/2004 Logan et al.  
6,716,244 B2 4/2004 Klaco  
6,719,781 B1 4/2004 Kim  
6,730,118 B2 5/2004 Spenser et al.  
6,730,121 B2 5/2004 Ortiz et al.  
6,733,525 B2 5/2004 Yang et al.  
6,752,813 B2 6/2004 Goldfarb et al.  
6,764,514 B1 7/2004 Li et al.  
6,764,518 B2 7/2004 Godin  
6,767,362 B2 7/2004 Schreck  
6,797,002 B2 9/2004 Spence et al.  
6,821,297 B2 11/2004 Snyders  
6,830,585 B1 12/2004 Artof et al.  
6,830,638 B2 12/2004 Boylan et al.  
6,893,460 B2 5/2005 Spenser et al.  
6,926,715 B1 8/2005 Hauck et al.  
6,951,571 B1 10/2005 Srivastava  
6,960,217 B2 11/2005 Bolduc  
6,964,684 B2 11/2005 Ortiz et al.  
6,974,476 B2 12/2005 McGuckin et al.  
7,011,681 B2 3/2006 Vesely  
7,018,406 B2 3/2006 Seguin et al.  
7,041,132 B2 5/2006 Quijano et al.  
7,077,861 B2 7/2006 Spence  
7,101,336 B2 9/2006 Miller  
7,101,395 B2 9/2006 Tremulis et al.  
7,101,396 B2 9/2006 Artof et al.  
7,112,207 B2 9/2006 Allen et al.  
7,137,184 B2 11/2006 Schreck  
7,172,625 B2 2/2007 Shu et al.  
7,198,646 B2 4/2007 Figulla et al.  
7,201,772 B2 4/2007 Schwammenthal  
7,226,467 B2 6/2007 Lucatero et al.  
7,226,477 B2 6/2007 Cox  
7,261,686 B2 8/2007 Couvillon, Jr.  
7,288,097 B2 10/2007 Séguin



(56)

## References Cited

## U.S. PATENT DOCUMENTS

7,288,111	B1	10/2007	Holloway et al.	7,951,195	B2	5/2011	Antonsson et al.
7,316,716	B2	1/2008	Egan	7,955,375	B2	6/2011	Agnew
7,329,279	B2	2/2008	Haug et al.	7,955,377	B2	6/2011	Melsheimer
7,335,213	B1	2/2008	Hyde et al.	7,955,384	B2	6/2011	Rafiee et al.
7,351,256	B2	4/2008	Hojeibane et al.	7,959,666	B2	6/2011	Salahieh et al.
7,374,571	B2	5/2008	Pease et al.	7,959,672	B2	6/2011	Salahieh et al.
7,374,573	B2	5/2008	Gabbay	7,967,833	B2	6/2011	Sterman et al.
7,377,938	B2	5/2008	Sarac et al.	7,967,857	B2	6/2011	Lane
7,381,218	B2	6/2008	Schreck	7,981,151	B2	7/2011	Rowe
7,381,219	B2	6/2008	Salahieh et al.	7,981,153	B2	7/2011	Fogarty et al.
7,404,824	B1	7/2008	Webler et al.	7,992,567	B2	8/2011	Hirotsuka et al.
7,422,306	B2	9/2008	Lane	7,993,393	B2	8/2011	Carpentier et al.
7,429,269	B2	9/2008	Schwammenthal	8,002,825	B2	8/2011	Letac et al.
7,442,204	B2	10/2008	Schwammenthal	8,002,826	B2	8/2011	Seguin
7,445,630	B2	11/2008	Lashinski et al.	8,016,877	B2	9/2011	Seguin et al.
7,455,677	B2	11/2008	Vargas et al.	8,016,882	B2	9/2011	Macoviak
7,455,688	B2	11/2008	Furst et al.	8,021,420	B2	9/2011	Dolan
7,462,162	B2	12/2008	Phan et al.	8,021,421	B2	9/2011	Fogarty et al.
7,481,838	B2	1/2009	Carpentier et al.	8,025,695	B2	9/2011	Fogarty et al.
7,510,575	B2	3/2009	Spenser et al.	8,029,518	B2	10/2011	Goldfarb et al.
7,513,909	B2	4/2009	Lane et al.	8,029,557	B2	10/2011	Sobrinho-Serrano et al.
7,524,331	B2	4/2009	Birdsall	8,029,564	B2	10/2011	Johnson et al.
7,527,646	B2	5/2009	Rahdert et al.	8,034,104	B2	10/2011	Carpentier et al.
7,556,632	B2	7/2009	Zadno	8,038,720	B2	10/2011	Wallace et al.
7,556,646	B2	7/2009	Yang et al.	8,043,360	B2	10/2011	McNamara et al.
7,563,267	B2	7/2009	Goldfarb et al.	8,048,138	B2	11/2011	Sullivan et al.
7,563,273	B2	7/2009	Goldfarb et al.	8,048,140	B2	11/2011	Purdy
7,582,111	B2	9/2009	Krolik et al.	8,048,153	B2	11/2011	Salahieh et al.
7,585,321	B2	9/2009	Cribier	8,052,592	B2	11/2011	Goldfarb et al.
7,597,711	B2	10/2009	Drews et al.	8,052,741	B2	11/2011	Bruszewski et al.
7,608,091	B2	10/2009	Goldfarb et al.	8,052,749	B2	11/2011	Salahieh et al.
7,611,534	B2	11/2009	Kapadia et al.	8,057,493	B2	11/2011	Goldfarb et al.
7,621,948	B2	11/2009	Hermann et al.	8,057,532	B2	11/2011	Hoffman
7,625,403	B2	12/2009	Krivoruchko	8,057,540	B2	11/2011	Letac et al.
7,632,302	B2	12/2009	Vreeman et al.	8,062,355	B2	11/2011	Figulla et al.
7,635,329	B2	12/2009	Goldfarb et al.	8,062,359	B2	11/2011	Marquez et al.
7,648,528	B2	1/2010	Styrc	8,070,708	B2	12/2011	Rottenberg et al.
7,655,015	B2	2/2010	Goldfarb et al.	8,070,800	B2	12/2011	Lock et al.
7,666,204	B2	2/2010	Thornton et al.	8,070,802	B2	12/2011	Lamphere et al.
7,682,380	B2	3/2010	Thornton et al.	8,070,804	B2	12/2011	Hyde
7,708,775	B2	5/2010	Rowe et al.	8,075,611	B2	12/2011	Milwee et al.
7,717,952	B2	5/2010	Case et al.	8,080,054	B2	12/2011	Rowe
7,717,955	B2	5/2010	Lane et al.	8,083,793	B2	12/2011	Lane et al.
7,731,741	B2	6/2010	Eidenschink	D652,927	S	1/2012	Braido et al.
7,736,388	B2	6/2010	Goldfarb et al.	D653,341	S	1/2012	Braido et al.
7,748,389	B2	7/2010	Salahieh et al.	8,092,518	B2	1/2012	Schreck
7,753,922	B2	7/2010	Starksen	8,092,520	B2	1/2012	Quadri
7,753,949	B2	7/2010	Lamphere et al.	8,092,521	B2	1/2012	Figulla et al.
7,758,595	B2	7/2010	Allen et al.	8,105,377	B2	1/2012	Liddicoat
7,758,632	B2	7/2010	Hojeibane et al.	8,109,996	B2	2/2012	Stacchino et al.
7,758,640	B2	7/2010	Vesely	8,118,866	B2	2/2012	Herrmann et al.
7,771,467	B2	8/2010	Svensson	8,133,270	B2	3/2012	Kheradvar et al.
7,771,469	B2	8/2010	Liddicoat	8,136,218	B2	3/2012	Millwee et al.
7,776,083	B2	8/2010	Vesely	8,137,398	B2	3/2012	Tuval et al.
7,780,726	B2	8/2010	Seguin	8,142,492	B2	3/2012	Forster et al.
7,799,069	B2	9/2010	Bailey et al.	8,142,494	B2	3/2012	Rahdert et al.
7,803,181	B2	9/2010	Furst et al.	8,142,496	B2	3/2012	Berrekouw
7,811,296	B2	10/2010	Goldfarb et al.	8,142,497	B2	3/2012	Friedman
7,811,316	B2	10/2010	Kalman et al.	8,147,504	B2	4/2012	Ino et al.
7,824,442	B2	11/2010	Salahieh et al.	8,157,852	B2	4/2012	Bloom et al.
7,837,645	B2	11/2010	Bessler et al.	8,157,853	B2	4/2012	Laske et al.
7,837,727	B2	11/2010	Goetz et al.	8,157,860	B2	4/2012	McNamara et al.
7,842,081	B2	11/2010	Yadin	8,163,008	B2	4/2012	Wilson et al.
7,850,725	B2	12/2010	Vardi et al.	8,163,014	B2	4/2012	Lane et al.
7,871,432	B2	1/2011	Bergin	D660,433	S	5/2012	Braido et al.
7,871,436	B2	1/2011	Ryan et al.	D660,967	S	5/2012	Braido et al.
7,887,583	B2	2/2011	Macoviak	8,167,894	B2	5/2012	Miles et al.
7,892,281	B2	2/2011	Seguin et al.	8,167,932	B2	5/2012	Bourang et al.
7,896,915	B2	3/2011	Guyenot et al.	8,167,935	B2	5/2012	McGuckin, Jr. et al.
7,914,544	B2	3/2011	Nguyen et al.	8,172,896	B2	5/2012	McNamara et al.
7,914,569	B2	3/2011	Nguyen et al.	8,172,898	B2	5/2012	Alferness et al.
7,927,370	B2	4/2011	Webler et al.	8,177,836	B2	5/2012	Lee et al.
7,942,927	B2	5/2011	Kaye et al.	8,182,528	B2	5/2012	Salahieh et al.
7,947,072	B2	5/2011	Yang et al.	8,211,169	B2	7/2012	Lane et al.
7,947,075	B2	5/2011	Goetz et al.	8,216,256	B2	7/2012	Raschdorf, Jr. et al.
				8,216,301	B2	7/2012	Bonhoeffer et al.
				8,221,492	B2	7/2012	Case et al.
				8,221,493	B2	7/2012	Boyle et al.
				8,226,710	B2	7/2012	Nguyen et al.



(56)

References Cited

U.S. PATENT DOCUMENTS

8,231,670 B2	7/2012	Salahieh et al.	8,801,776 B2	8/2014	House et al.
8,236,045 B2	8/2012	Benichou et al.	8,808,366 B2	8/2014	Braido et al.
8,236,049 B2	8/2012	Rowe et al.	8,840,663 B2	9/2014	Salahieh et al.
8,252,042 B2	8/2012	McNamara et al.	8,840,664 B2	9/2014	Karapetian et al.
8,252,051 B2	8/2012	Chau et al.	8,845,722 B2	9/2014	Gabbay
8,252,052 B2	8/2012	Salahieh et al.	8,852,261 B2	10/2014	White
8,257,390 B2	9/2012	Carley et al.	8,852,272 B2 *	10/2014	Gross ..... A61B 17/122
8,267,988 B2	9/2012	Hamer et al.			623/2.18
8,277,501 B2	10/2012	Chalekian et al.	8,870,948 B1	10/2014	Erzberger et al.
8,287,591 B2	10/2012	Keidar et al.	8,870,949 B2	10/2014	Rowe
8,298,280 B2	10/2012	Yadin et al.	8,870,950 B2	10/2014	Hacohen
8,303,653 B2	11/2012	Bonhoeffer et al.	8,876,800 B2	11/2014	Behan
8,308,798 B2	11/2012	Pintor et al.	8,888,843 B2	11/2014	Khairkhahan et al.
8,317,853 B2	11/2012	Agnew	8,894,702 B2	11/2014	Quadri et al.
8,317,855 B2	11/2012	Gregorich et al.	8,900,294 B2	12/2014	Paniagua et al.
8,323,335 B2	12/2012	Rowe et al.	8,900,295 B2	12/2014	Migliazza et al.
8,328,868 B2	12/2012	Paul et al.	8,906,083 B2	12/2014	Obermiller et al.
8,337,541 B2	12/2012	Quadri et al.	8,911,455 B2	12/2014	Quadri et al.
8,343,174 B2	1/2013	Goldfard et al.	8,911,489 B2	12/2014	Ben-Muvhar
8,343,213 B2	1/2013	Salahieh et al.	8,911,493 B2	12/2014	Rowe et al.
8,348,999 B2	1/2013	Kheradvar et al.	8,932,343 B2	1/2015	Alkhatib et al.
8,366,767 B2	2/2013	Zhang	8,945,177 B2	2/2015	Dell et al.
8,372,140 B2	2/2013	Hoffman et al.	8,961,595 B2	2/2015	Alkhatib
8,377,119 B2	2/2013	Drews et al.	8,979,922 B2	3/2015	Jayasinghe et al.
8,398,708 B2	3/2013	Meiri et al.	8,986,370 B2	3/2015	Annest
8,403,981 B2	3/2013	Forster et al.	8,986,373 B2	3/2015	Chau et al.
8,403,983 B2	3/2013	Quadri et al.	8,986,375 B2	3/2015	Garde et al.
8,408,214 B2	4/2013	Spenser	8,992,599 B2	3/2015	Thubrikar et al.
8,414,644 B2	4/2013	Quadri et al.	8,992,604 B2 *	3/2015	Gross ..... A61F 2/2412
8,425,593 B2	4/2013	Braido			623/2.11
8,430,934 B2	4/2013	Das	8,992,608 B2	3/2015	Haug et al.
8,444,689 B2	5/2013	Zhang	8,998,982 B2 *	4/2015	Richter ..... A61F 2/2418
8,449,599 B2	5/2013	Chau et al.			623/2.14
8,449,625 B2	5/2013	Campbell et al.	9,005,273 B2	4/2015	Salahieh et al.
8,454,686 B2	6/2013	Alkhatib	9,011,468 B2	4/2015	Ketai et al.
8,460,365 B2	6/2013	Haverkost et al.	9,011,527 B2	4/2015	Li et al.
8,474,460 B2	7/2013	Barrett et al.	9,017,399 B2 *	4/2015	Gross ..... A61F 2/2418
8,500,821 B2	8/2013	Sobrino-Serrano et al.			623/2.11
8,512,400 B2	8/2013	Tran et al.	D730,520 S	5/2015	Braido et al.
8,529,431 B2	9/2013	Baker et al.	D730,521 S	5/2015	Braido et al.
8,539,662 B2	9/2013	Stacchino et al.	9,023,100 B2 *	5/2015	Quadri ..... A61F 2/2418
8,545,544 B2	10/2013	Spenser et al.			623/2.11
8,551,160 B2	10/2013	Figulla et al.	9,034,032 B2	5/2015	McLean et al.
8,551,161 B2	10/2013	Dolan	9,034,033 B2	5/2015	McLean et al.
8,562,672 B2	10/2013	Bonhoeffer et al.	9,039,757 B2	5/2015	McLean et al.
8,568,475 B2	10/2013	Nguyen et al.	D732,666 S	6/2015	Nguyen et al.
8,579,964 B2	11/2013	Lane et al.	9,050,188 B2	6/2015	Schweich et al.
8,579,965 B2	11/2013	Bonhoeffer et al.	9,060,858 B2	6/2015	Thornton et al.
8,585,755 B2	11/2013	Chau et al.	9,072,603 B2	7/2015	Tuval et al.
8,585,756 B2	11/2013	Bonhoeffer et al.	9,084,676 B2	7/2015	Chau et al.
8,591,460 B2	11/2013	Wilson et al.	9,095,434 B2	8/2015	Rowe
8,591,570 B2	11/2013	Revuelta et al.	9,119,719 B2 *	9/2015	Zipory ..... A61B 17/068
8,623,075 B2	1/2014	Murray et al.	9,125,738 B2	9/2015	Figulla et al.
8,623,080 B2	1/2014	Fogarty et al.	9,125,740 B2	9/2015	Morriss et al.
8,628,569 B2	1/2014	Benichou et al.	9,132,006 B2	9/2015	Spenser et al.
8,628,570 B2	1/2014	Seguin	9,132,009 B2 *	9/2015	Hacohen ..... A61B 17/068
8,628,571 B1	1/2014	Hacohen et al.	9,138,312 B2	9/2015	Tuval et al.
8,652,203 B2	2/2014	Quadri et al.	9,155,619 B2	10/2015	Liu et al.
8,652,204 B2	2/2014	Quill et al.	9,173,659 B2	11/2015	Bodewadt et al.
8,657,872 B2	2/2014	Seguin	9,173,738 B2	11/2015	Murray et al.
8,663,322 B2	3/2014	Keranen	9,220,594 B2	12/2015	Braido et al.
8,673,020 B2	3/2014	Sobrino-Serrano et al.	9,226,820 B2	1/2016	Braido et al.
8,679,174 B2	3/2014	Ottma et al.	9,226,839 B1	1/2016	Kariniemi et al.
8,685,086 B2	4/2014	Navia et al.	9,232,995 B2	1/2016	Kovalsky et al.
8,696,742 B2	4/2014	Pintor et al.	9,241,790 B2	1/2016	Lane et al.
8,728,155 B2	5/2014	Montorfano et al.	9,241,791 B2	1/2016	Braido et al.
8,734,507 B2	5/2014	Keranen	9,241,792 B2	1/2016	Benichou et al.
8,747,460 B2	6/2014	Tuval et al.	9,241,794 B2	1/2016	Braido et al.
8,771,345 B2	7/2014	Tuval et al.	9,248,014 B2	2/2016	Lane et al.
8,784,472 B2	7/2014	Eidenschink	9,277,994 B2 *	3/2016	Miller ..... A61F 2/2466
8,784,479 B2	7/2014	Antonsson et al.	9,289,290 B2	3/2016	Alkhatib et al.
8,784,481 B2	7/2014	Alkhatib et al.	9,289,291 B2	3/2016	Gorman et al.
8,795,355 B2	8/2014	Alkhatib	9,295,550 B2	3/2016	Nguyen et al.
8,795,356 B2	8/2014	Quadri et al.	9,295,551 B2	3/2016	Straubinger et al.
8,795,357 B2	8/2014	Yohanani et al.	9,295,552 B2	3/2016	McLean et al.
			9,301,836 B2	4/2016	Buchbinder et al.
			D755,384 S	5/2016	Pesce et al.
			9,326,852 B2	5/2016	Spenser
			9,326,876 B2	5/2016	Acosta et al.



(56)

References Cited

U.S. PATENT DOCUMENTS

9,345,573 B2	5/2016	Nyuli et al.	
9,387,078 B2 *	7/2016	Gross .....	A61F 2/2454
9,421,098 B2	8/2016	Gifford et al.	
9,427,303 B2	8/2016	Liddy et al.	
9,427,316 B2	8/2016	Schweich, Jr. et al.	
9,439,757 B2	9/2016	Wallace et al.	
9,463,102 B2	10/2016	Kelly	
9,474,599 B2	10/2016	Keranan	
9,474,638 B2	10/2016	Robinson et al.	
9,480,559 B2	11/2016	Vidlund et al.	
9,492,273 B2	11/2016	Wallace et al.	
9,498,314 B2	11/2016	Behan	
9,532,870 B2	1/2017	Cooper et al.	
9,554,897 B2	1/2017	Lane et al.	
9,554,899 B2	1/2017	Granada et al.	
9,561,103 B2	2/2017	Granada et al.	
9,566,152 B2	2/2017	Schweich et al.	
9,629,716 B2	4/2017	Seguin	
9,662,203 B2	5/2017	Sheahan et al.	
9,681,952 B2	6/2017	Hacohen et al.	
9,717,591 B2	8/2017	Chau et al.	
9,743,932 B2	8/2017	Amplatz et al.	
9,763,657 B2 *	9/2017	Hacohen .....	A61F 2/2418
9,763,817 B2	9/2017	Roeder	
9,770,256 B2	9/2017	Cohen et al.	
D800,908 S	10/2017	Hariton et al.	
9,788,941 B2	10/2017	Hacohen	
9,895,226 B1	2/2018	Harari et al.	
9,987,132 B1	6/2018	Hariton et al.	
10,010,414 B2	7/2018	Cooper et al.	
10,105,222 B1	10/2018	Metchik et al.	
10,123,873 B1	11/2018	Metchik et al.	
10,143,552 B2	12/2018	Wallace et al.	
10,149,761 B2	12/2018	Granada et al.	
10,154,906 B2	12/2018	Granada et al.	
10,182,908 B2	1/2019	Tubishevitz et al.	
10,206,668 B2	2/2019	Mcgoldrick et al.	
10,226,341 B2 *	3/2019	Gross .....	A61F 2/246
10,245,143 B2	4/2019	Gross et al.	
10,258,471 B2	4/2019	Lutter et al.	
10,292,816 B2	5/2019	Raanani et al.	
10,321,995 B1	6/2019	Christianson et al.	
10,322,020 B2	6/2019	Lam et al.	
10,327,895 B2	6/2019	Lozonschi et al.	
10,376,361 B2 *	8/2019	Gross .....	A61F 2/246
10,390,952 B2	8/2019	Hariton et al.	
10,456,256 B2	10/2019	Braido et al.	
10,507,108 B2	12/2019	Delgado et al.	
10,512,456 B2 *	12/2019	Hacohen .....	A61F 2/2409
10,517,719 B2 *	12/2019	Miller .....	A61F 2/2466
10,531,866 B2	1/2020	Hariton et al.	
10,531,872 B2	1/2020	Hacohen et al.	
10,548,731 B2	2/2020	Lashinski et al.	
10,575,948 B2	3/2020	Iamberger et al.	
10,595,992 B2	3/2020	Chambers	
10,610,358 B2	4/2020	Vidlund et al.	
10,631,871 B2	4/2020	Goldfarb et al.	
10,667,912 B2	6/2020	Dixon et al.	
10,695,173 B2	6/2020	Gross et al.	
10,702,385 B2 *	7/2020	Hacohen .....	A61F 2/246
10,835,377 B2	11/2020	Hacohen et al.	
10,842,627 B2	11/2020	Delgado et al.	
10,856,972 B2	12/2020	Hariton et al.	
10,874,514 B2	12/2020	Dixon et al.	
10,888,422 B2	1/2021	Hariton et al.	
10,888,425 B2	1/2021	Delgado et al.	
10,888,644 B2	1/2021	Ratz et al.	
10,905,552 B2	2/2021	Dixon et al.	
10,905,554 B2	2/2021	Cao	
10,918,483 B2	2/2021	Metchik et al.	
10,925,732 B2	2/2021	Delgado et al.	
10,945,843 B2	3/2021	Delgado et al.	
10,945,844 B2	3/2021	McCann et al.	
10,959,846 B2	3/2021	Marr et al.	
10,993,809 B2	5/2021	McCann et al.	
11,065,114 B2	7/2021	Raanani et al.	
11,083,582 B2	8/2021	McCann et al.	
11,147,672 B2	10/2021	McCann et al.	
11,179,240 B2	11/2021	Delgado et al.	
11,291,545 B2	4/2022	Hacohen	
11,291,546 B2 *	4/2022	Gross .....	A61F 2/2436
11,291,547 B2 *	4/2022	Gross .....	A61B 17/122
11,291,844 B2 *	4/2022	Gross .....	A61F 2/2436
11,304,806 B2	4/2022	Hariton et al.	
11,389,297 B2	7/2022	Franklin et al.	
11,426,155 B2 *	8/2022	Hacohen .....	A61F 2/2457
11,517,429 B2 *	12/2022	Gross .....	A61F 2/2418
11,517,436 B2 *	12/2022	Hacohen .....	A61F 2/2466
2001/0002445 A1	5/2001	Vesely	
2001/0005787 A1	6/2001	Oz	
2001/0021872 A1	9/2001	Bailey et al.	
2001/0056295 A1	12/2001	Solem	
2002/0013571 A1	1/2002	Goldfarb et al.	
2002/0032481 A1	3/2002	Gabbay	
2002/0099436 A1	7/2002	Thornton et al.	
2002/0151970 A1	10/2002	Garrison et al.	
2002/0177894 A1	11/2002	Acosta et al.	
2003/0009236 A1	1/2003	Godin	
2003/0036791 A1	2/2003	Bonhoeft et al.	
2003/0060846 A1	3/2003	Egnelov et al.	
2003/0060875 A1	3/2003	Wittens	
2003/0069635 A1	4/2003	Cartledge	
2003/0074052 A1	4/2003	Besselink	
2003/0083742 A1	5/2003	Spence et al.	
2003/0105519 A1	6/2003	Fasol et al.	
2003/0120340 A1	6/2003	Liska et al.	
2003/0158578 A1	8/2003	Pantages et al.	
2004/0010272 A1	1/2004	Manetakis et al.	
2004/0030382 A1	2/2004	St. Goar et al.	
2004/0039414 A1	2/2004	Carley et al.	
2004/0039442 A1	2/2004	St. Goar et al.	
2004/0093060 A1	5/2004	Seguin et al.	
2004/0122503 A1	6/2004	Campbell et al.	
2004/0122514 A1	6/2004	Fogarty et al.	
2004/0133267 A1	7/2004	Lane	
2004/0143315 A1	7/2004	Bruun et al.	
2004/0176839 A1	9/2004	Huynh et al.	
2004/0186558 A1	9/2004	Pavcnik et al.	
2004/0186565 A1	9/2004	Schreck	
2004/0186566 A1	9/2004	Hindrichs et al.	
2004/0210244 A1	10/2004	Vargas et al.	
2004/0210304 A1	10/2004	Seguin et al.	
2004/0220593 A1	11/2004	Greenhalgh	
2004/0225354 A1	11/2004	Allen et al.	
2004/0236354 A1	11/2004	Seguin	
2004/0249433 A1	12/2004	Freitag	
2004/0260389 A1	12/2004	Case et al.	
2004/0260394 A1	12/2004	Douk et al.	
2005/0004668 A1	1/2005	Aklog et al.	
2005/0021056 A1	1/2005	St. Goar et al.	
2005/0027305 A1	2/2005	Shiu et al.	
2005/0027348 A1	2/2005	Case et al.	
2005/0038494 A1	2/2005	Eidenschink	
2005/0055086 A1	3/2005	Stobie	
2005/0075731 A1	4/2005	Artof et al.	
2005/0080430 A1	4/2005	Wright et al.	
2005/0085900 A1	4/2005	Case et al.	
2005/0137686 A1	6/2005	Salahieh et al.	
2005/0137688 A1	6/2005	Salahieh et al.	
2005/0137689 A1	6/2005	Salahieh et al.	
2005/0137690 A1	6/2005	Salahieh et al.	
2005/0137691 A1	6/2005	Salahieh et al.	
2005/0137692 A1	6/2005	Haug et al.	
2005/0137693 A1	6/2005	Haug et al.	
2005/0137695 A1	6/2005	Salahieh et al.	
2005/0137697 A1	6/2005	Salahieh et al.	
2005/0137699 A1	6/2005	Salahieh et al.	
2005/0143809 A1	6/2005	Salahieh et al.	
2005/0149160 A1	7/2005	McFerran	
2005/0154443 A1	7/2005	Linder et al.	
2005/0182486 A1	8/2005	Gabbay	
2005/0197695 A1	9/2005	Stacchino et al.	
2005/0203549 A1	9/2005	Realyvasquez	
2005/0203618 A1	9/2005	Sharkawy et al.	



(56)

References Cited

U.S. PATENT DOCUMENTS

2005/0216079	A1	9/2005	MaCoviak		2008/0004697	A1	1/2008	Lichtenstein et al.
2005/0234508	A1	10/2005	Cummins et al.		2008/0051703	A1	2/2008	Thornton et al.
2005/0240200	A1*	10/2005	Bergheim .....	A61F 2/2427 623/2.11	2008/0065204	A1	3/2008	Macoviak et al.
2005/0251251	A1	11/2005	Cribier		2008/0071361	A1	3/2008	Tuval et al.
2005/0256566	A1	11/2005	Gabbay		2008/0071363	A1	3/2008	Tuval et al.
2005/0267573	A9	12/2005	Macoviak et al.		2008/0071366	A1	3/2008	Tuval et al.
2006/0004439	A1	1/2006	Spenser et al.		2008/0071369	A1	3/2008	Tuval et al.
2006/0004469	A1	1/2006	Sokel		2008/0077235	A1	3/2008	Kirson
2006/0015171	A1	1/2006	Armstrong		2008/0082083	A1	4/2008	Forde et al.
2006/0020275	A1	1/2006	Goldfarb et al.		2008/0082159	A1	4/2008	Tseng et al.
2006/0020327	A1	1/2006	Lashinski et al.		2008/0082166	A1	4/2008	Styrc et al.
2006/0020333	A1	1/2006	Lashinski et al.		2008/0086204	A1	4/2008	Rankin
2006/0041189	A1	2/2006	Vancaillie		2008/0091261	A1	4/2008	Long et al.
2006/0052867	A1	3/2006	Revuelta et al.		2008/0097595	A1	4/2008	Gabbay
2006/0089627	A1	4/2006	Burnett et al.		2008/0132989	A1	6/2008	Snow et al.
2006/0111773	A1	5/2006	Rittgers et al.		2008/0140003	A1	6/2008	Bei et al.
2006/0116750	A1	6/2006	Herbert et al.		2008/0147182	A1	6/2008	Righini et al.
2006/0122692	A1	6/2006	Gilad et al.		2008/0161910	A1	7/2008	Revuelta et al.
2006/0135964	A1	6/2006	Vesley		2008/0167705	A1	7/2008	Agnew
2006/0155357	A1	7/2006	Melsheimer		2008/0167714	A1	7/2008	St. Goar et al.
2006/0047297	A1	8/2006	Case		2008/0188929	A1	8/2008	Schreck
2006/0178700	A1	8/2006	Quinn		2008/0195200	A1	8/2008	Vidlund et al.
2006/0178740	A1	8/2006	Stacchino et al.		2008/0200980	A1	8/2008	Robin et al.
2006/0184203	A1	8/2006	Martin et al.		2008/0208328	A1	8/2008	Antocci et al.
2006/0190036	A1	8/2006	Wendel et al.		2008/0208332	A1	8/2008	Lamphere et al.
2006/0190038	A1	8/2006	Carley et al.		2008/0221672	A1	9/2008	Lamphere et al.
2006/0195183	A1	8/2006	Navia et al.		2008/0234814	A1	9/2008	Salahieh et al.
2006/0195184	A1	8/2006	Lane et al.		2008/0243245	A1	10/2008	Thambar et al.
2006/0201519	A1	9/2006	Frazier et al.		2008/0255580	A1	10/2008	Hoffman et al.
2006/0212111	A1	9/2006	Case et al.		2008/0262609	A1	10/2008	Gross et al.
2006/0229708	A1	10/2006	Powell et al.		2008/0269879	A1	10/2008	Sathe et al.
2006/0241656	A1	10/2006	Starksen et al.		2008/0281411	A1	11/2008	Berrekouw
2006/0241745	A1	10/2006	Solem		2008/0294234	A1	11/2008	Hartley et al.
2006/0241748	A1	10/2006	Lee et al.		2009/0005863	A1*	1/2009	Goetz ..... A61F 2/2418 623/2.18
2006/0247680	A1	11/2006	Amplatz et al.		2009/0036966	A1	2/2009	O'Connor et al.
2006/0253191	A1	11/2006	Salahieh et al.		2009/0054969	A1	2/2009	Salahieh et al.
2006/0259136	A1	11/2006	Nguyen et al.		2009/0082844	A1	3/2009	Zacharias et al.
2006/0259137	A1*	11/2006	Artof .....	A61F 2/243 623/2.11	2009/0088836	A1	4/2009	Bishop et al.
2006/0271166	A1	11/2006	Thill et al.		2009/0099554	A1	4/2009	Forster et al.
2006/0271171	A1	11/2006	McQuinn et al.		2009/0099650	A1	4/2009	Bolduc et al.
2006/0282150	A1	12/2006	Olson et al.		2009/0112159	A1	4/2009	Slattery et al.
2006/0287719	A1	12/2006	Rowe et al.		2009/0125098	A1	5/2009	Chuter
2007/0016286	A1	1/2007	Herrmann et al.		2009/0157175	A1	6/2009	Benichou
2007/0016288	A1	1/2007	Gurskis et al.		2009/0163934	A1	6/2009	Raschdorf, Jr. et al.
2007/0027528	A1	2/2007	Agnew		2009/0171363	A1	7/2009	Chocron
2007/0027549	A1	2/2007	Godin		2009/0177278	A1	7/2009	Spence
2007/0038293	A1	2/2007	St. Goar et al.		2009/0210052	A1	8/2009	Forster et al.
2007/0038295	A1	2/2007	Case et al.		2009/0222081	A1	9/2009	Linder et al.
2007/0043435	A1	2/2007	Seguin et al.		2009/0240320	A1	9/2009	Tuval et al.
2007/0055340	A1	3/2007	Pryor		2009/0241656	A1	10/2009	Jacquemin
2007/0056346	A1	3/2007	Spenser et al.		2009/0259306	A1	10/2009	Rowe
2007/0078510	A1	4/2007	Ryan		2009/0264859	A1	10/2009	Mas
2007/0112422	A1	5/2007	Dehdashtian		2009/0264994	A1	10/2009	Saadat
2007/0118151	A1	5/2007	Davidson		2009/0276040	A1	11/2009	Rowe et al.
2007/0162103	A1	7/2007	Case et al.		2009/0281619	A1	11/2009	Le et al.
2007/0162107	A1	7/2007	Haug et al.		2009/0287304	A1	11/2009	Dahlgren et al.
2007/0162111	A1	7/2007	Fukamachi et al.		2009/0299449	A1	12/2009	Styrc
2007/0173932	A1	7/2007	Cali et al.		2009/0306768	A1	12/2009	Quardi
2007/0197858	A1	8/2007	Goldfarb et al.		2009/0319037	A1	12/2009	Rowe et al.
2007/0198077	A1	8/2007	Cully et al.		2010/0022823	A1	1/2010	Goldfarb
2007/0198097	A1	8/2007	Zegdi		2010/0023117	A1	1/2010	Yoganathan et al.
2007/0213810	A1	9/2007	Newhauser et al.		2010/0023120	A1	1/2010	Holecsek et al.
2007/0213813	A1	9/2007	Von Segesser et al.		2010/0036479	A1	2/2010	Hill et al.
2007/0219630	A1	9/2007	Chu		2010/0049313	A1	2/2010	Alon et al.
2007/0225759	A1	9/2007	Thommen et al.		2010/0069852	A1	3/2010	Kelley
2007/0225760	A1	9/2007	Moszner et al.		2010/0076548	A1	3/2010	Konno
2007/0233186	A1	10/2007	Meng		2010/0100167	A1	4/2010	Bortlein et al.
2007/0233237	A1	10/2007	Krivoruchko		2010/0114299	A1	5/2010	Ben-Muvhar et al.
2007/0239272	A1	10/2007	Navia et al.		2010/0131054	A1	5/2010	Tuval et al.
2007/0239273	A1	10/2007	Allen		2010/0137979	A1	6/2010	Tuval et al.
2007/0244546	A1	10/2007	Francis		2010/0160958	A1	6/2010	Clark
2007/0255400	A1	11/2007	Parravicini et al.		2010/0161036	A1*	6/2010	Pintor ..... A61F 2/2433 623/2.11
2008/0004688	A1	1/2008	Spenser et al.		2010/0161042	A1	6/2010	Maisano et al.
					2010/0174363	A1	7/2010	Castro
					2010/0179643	A1	7/2010	Shalev
					2010/0179648	A1	7/2010	Richter et al.
					2010/0179649	A1	7/2010	Richter et al.



(56)

References Cited

U.S. PATENT DOCUMENTS

2010/0185277	A1	7/2010	Braido et al.	2011/0257721	A1	10/2011	Tabor
2010/0217382	A1	8/2010	Chau et al.	2011/0257729	A1	10/2011	Spenser et al.
2010/0222810	A1	9/2010	DeBeer et al.	2011/0257736	A1	10/2011	Marquez et al.
2010/0228285	A1	9/2010	Miles et al.	2011/0257737	A1	10/2011	Fogarty et al.
2010/0234940	A1	9/2010	Dolan	2011/0264191	A1	10/2011	Rothstein
2010/0249908	A1	9/2010	Chau et al.	2011/0264196	A1	10/2011	Savage et al.
2010/0249917	A1	9/2010	Zhang	2011/0264198	A1	10/2011	Murray, III et al.
2010/0256737	A1	10/2010	Pollock et al.	2011/0264199	A1	10/2011	Tran et al.
2010/0262232	A1	10/2010	Annest	2011/0264200	A1	10/2011	Tran et al.
2010/0280603	A1	11/2010	Maisano et al.	2011/0264201	A1	10/2011	Yeung
2010/0280606	A1	11/2010	Naor	2011/0264202	A1	10/2011	Murray, III et al.
2010/0312333	A1	12/2010	Navia et al.	2011/0264203	A1	10/2011	Dwork et al.
2010/0324595	A1	12/2010	Linder et al.	2011/0264206	A1	10/2011	Tabor
2010/0331971	A1	12/2010	Keranen et al.	2011/0264208	A1	10/2011	Duffy
2011/0004227	A1	1/2011	Goldfarb et al.	2011/0270276	A1	11/2011	Rothstein et al.
2011/0004296	A1	1/2011	Lutter et al.	2011/0271967	A1	11/2011	Mortier et al.
2011/0004299	A1	1/2011	Navia et al.	2011/0282438	A1	11/2011	Drews et al.
2011/0015729	A1	1/2011	Jimenez et al.	2011/0282439	A1*	11/2011	Thill ..... A61F 2/90 623/2.17
2011/0015731	A1	1/2011	Carpentier et al.	2011/0282440	A1	11/2011	Cao
2011/0015739	A1	1/2011	Cheung et al.	2011/0283514	A1	11/2011	Fogarty et al.
2011/0021985	A1	1/2011	Spargias	2011/0288632	A1	11/2011	White
2011/0022165	A1	1/2011	Oba et al.	2011/0288634	A1	11/2011	Tuval et al.
2011/0178597	A9	1/2011	Navia et al.	2011/0295354	A1	12/2011	Bueche et al.
2011/0029067	A1	2/2011	Mcguckin, Jr. et al.	2011/0295363	A1	12/2011	Girard et al.
2011/0029072	A1	2/2011	Gabbay	2011/0301688	A1	12/2011	Dolan
2011/0040374	A1	2/2011	Goetz et al.	2011/0301698	A1	12/2011	Miller et al.
2011/0040375	A1	2/2011	Letac et al.	2011/0301701	A1	12/2011	Padala et al.
2011/0046662	A1	2/2011	Moszner et al.	2011/0301702	A1	12/2011	Rust et al.
2011/0054466	A1	3/2011	Rothstein et al.	2011/0306916	A1	12/2011	Nitzan et al.
2011/0054596	A1	3/2011	Taylor	2011/0307049	A1	12/2011	Kao
2011/0054598	A1	3/2011	Johnson	2011/0313452	A1	12/2011	Carley et al.
2011/0066233	A1	3/2011	Thornton et al.	2011/0313515	A1	12/2011	Quadri et al.
2011/0071626	A1	3/2011	Wright et al.	2011/0319989	A1*	12/2011	Lane ..... A61F 2/2412 623/2.37
2011/0077730	A1	3/2011	Fentster	2011/0319991	A1	12/2011	Hariton et al.
2011/0082538	A1	4/2011	Dahlgren et al.	2012/0010694	A1	1/2012	Lutter et al.
2011/0087322	A1	4/2011	Letac et al.	2012/0016468	A1	1/2012	Robin et al.
2011/0093063	A1	4/2011	Schreck	2012/0022629	A1	1/2012	Perera et al.
2011/0098525	A1	4/2011	Kermode et al.	2012/0022633	A1	1/2012	Olson et al.
2011/0106247	A1	5/2011	Miller et al.	2012/0022637	A1	1/2012	Ben-Movhar et al.
2011/0112625	A1	5/2011	Ben-Muvhar et al.	2012/0022639	A1	1/2012	Hacohen et al.
2011/0112632	A1	5/2011	Chau et al.	2012/0022640	A1	1/2012	Gross et al.
2011/0113768	A1	5/2011	Bauer et al.	2012/0035703	A1	2/2012	Lutter et al.
2011/0118830	A1	5/2011	Liddicoat et al.	2012/0035713	A1	2/2012	Lutter et al.
2011/0125257	A1	5/2011	Seguin et al.	2012/0035722	A1	2/2012	Tuval et al.
2011/0125258	A1	5/2011	Centola	2012/0041547	A1	2/2012	Duffy et al.
2011/0137326	A1	6/2011	Bachman	2012/0041551	A1	2/2012	Spenser et al.
2011/0137397	A1	6/2011	Chau et al.	2012/0046738	A1	2/2012	Lau et al.
2011/0137409	A1	6/2011	Yang et al.	2012/0046742	A1	2/2012	Tuval et al.
2011/0137410	A1	6/2011	Hacohen	2012/0053676	A1	3/2012	Ku et al.
2011/0144742	A1	6/2011	Madrid et al.	2012/0053680	A1	3/2012	Bolling et al.
2011/0166636	A1	7/2011	Rowe	2012/0053682	A1	3/2012	Kovalsky et al.
2011/0172784	A1	7/2011	Richter	2012/0053688	A1	3/2012	Fogarty et al.
2011/0184510	A1	7/2011	Maisano et al.	2012/0059454	A1	3/2012	Millwee et al.
2011/0190877	A1	8/2011	Lane et al.	2012/0059458	A1	3/2012	Buchbinder et al.
2011/0190879	A1	8/2011	Bobo et al.	2012/0065464	A1	3/2012	Ellis et al.
2011/0202076	A1	8/2011	Richter	2012/0078237	A1	3/2012	Wang et al.
2011/0208283	A1	8/2011	Rust	2012/0078353	A1	3/2012	Quadri et al.
2011/0208293	A1	8/2011	Tabor	2012/0078357	A1	3/2012	Conklin
2011/0208298	A1	8/2011	Tuval et al.	2012/0083832	A1	4/2012	Delaloye et al.
2011/0213459	A1	9/2011	Garrison et al.	2012/0083839	A1	4/2012	Letac et al.
2011/0213461	A1	9/2011	Seguin et al.	2012/0083879	A1	4/2012	Eberhardt et al.
2011/0218619	A1	9/2011	Benichou et al.	2012/0089223	A1	4/2012	Nguyen et al.
2011/0218620	A1	9/2011	Meiri et al.	2012/0101570	A1	4/2012	Tuval et al.
2011/0224785	A1*	9/2011	Hacohen ..... A61F 2/2457 623/2.18	2012/0101571	A1	4/2012	Thambar et al.
2011/0238159	A1	9/2011	Guyenot et al.	2012/0101572	A1	4/2012	Kovalsky et al.
2011/0245911	A1	10/2011	Quill et al.	2012/0123511	A1	5/2012	Brown
2011/0245917	A1	10/2011	Savage et al.	2012/0123529	A1	5/2012	Levi et al.
2011/0251675	A1	10/2011	Dwork	2012/0123530	A1	5/2012	Carpentier et al.
2011/0251676	A1	10/2011	Sweeney et al.	2012/0130473	A1	5/2012	Norris et al.
2011/0251678	A1	10/2011	Eidenschink et al.	2012/0130474	A1	5/2012	Buckley
2011/0251679	A1	10/2011	Weimeyer et al.	2012/0130475	A1	5/2012	Shaw
2011/0251680	A1	10/2011	Tran et al.	2012/0136434	A1	5/2012	Carpentier et al.
2011/0251682	A1	10/2011	Murray, III et al.	2012/0150218	A1	6/2012	Sandgren et al.
2011/0251683	A1	10/2011	Tabor	2012/0165915	A1	6/2012	Melsheimer et al.
				2012/0165930	A1	6/2012	Gifford, III et al.
				2012/0179244	A1	7/2012	Schankereli et al.
				2012/0197292	A1	8/2012	Chin-Chen et al.



(56)

References Cited

U.S. PATENT DOCUMENTS

2012/0283824 A1	11/2012	Lutter et al.	2014/0214157 A1	7/2014	Börtlein et al.
2012/0290062 A1	11/2012	McNamara et al.	2014/0214159 A1	7/2014	Vidlund et al.
2012/0296360 A1	11/2012	Norris et al.	2014/0222136 A1	8/2014	Geist et al.
2012/0296418 A1	11/2012	Bonyuet et al.	2014/0222142 A1	8/2014	Kovalsky et al.
2012/0300063 A1	11/2012	Majkrzak et al.	2014/0236287 A1	8/2014	Clague et al.
2012/0310328 A1	12/2012	Olson et al.	2014/0236289 A1	8/2014	Alkhatib
2012/0323316 A1	12/2012	Chau et al.	2014/0249622 A1	9/2014	Carmi et al.
2012/0330408 A1	12/2012	Hillukka et al.	2014/0257461 A1	9/2014	Robinson et al.
2013/0006347 A1	1/2013	McHugo	2014/0257467 A1*	9/2014	Lane ..... A61F 2/2418 623/2.37
2013/0018450 A1	1/2013	Hunt	2014/0257475 A1	9/2014	Gross et al.
2013/0018458 A1	1/2013	Yohanani et al.	2014/0257476 A1	9/2014	Montorfano et al.
2013/0030519 A1	1/2013	Tran et al.	2014/0277358 A1	9/2014	Slazas
2013/0035759 A1	2/2013	Gross et al.	2014/0277409 A1	9/2014	Bortlein et al.
2013/0041451 A1	2/2013	Patterson et al.	2014/0277411 A1	9/2014	Börtlein et al.
2013/0046373 A1	2/2013	Cartledge et al.	2014/0277412 A1	9/2014	Börtlein et al.
2013/0066341 A1	3/2013	Ketai et al.	2014/0277418 A1	9/2014	Miller
2013/0066342 A1	3/2013	Dell	2014/0277422 A1	9/2014	Ratz et al.
2013/0079872 A1	3/2013	Gallagher	2014/0277427 A1	9/2014	Ratz et al.
2013/0116780 A1	5/2013	Miller et al.	2014/0296962 A1	10/2014	Cartledge et al.
2013/0123896 A1	5/2013	Bloss et al.	2014/0296969 A1	10/2014	Tegels et al.
2013/0123900 A1	5/2013	Eblacas et al.	2014/0324164 A1	10/2014	Gross et al.
2013/0150945 A1	6/2013	Crawford et al.	2014/0331475 A1	11/2014	Duffy et al.
2013/0150956 A1	6/2013	Yohanani et al.	2014/0336744 A1	11/2014	Tani et al.
2013/0158647 A1	6/2013	Norris et al.	2014/0343670 A1	11/2014	Bakis et al.
2013/0165930 A1	6/2013	Lehmann	2014/0350662 A1	11/2014	Vaturi
2013/0166017 A1	6/2013	Cartledge et al.	2014/0350670 A1	11/2014	Keränen
2013/0166022 A1	6/2013	Conklin	2014/0358222 A1	12/2014	Gorman, III et al.
2013/0172978 A1	7/2013	Vidlund et al.	2014/0358224 A1	12/2014	Tegels et al.
2013/0172992 A1	7/2013	Gross et al.	2014/0379065 A1	12/2014	Johnson et al.
2013/0190861 A1	7/2013	Chau et al.	2014/0379074 A1	12/2014	Spence et al.
2013/0211501 A1	8/2013	Buckley et al.	2014/0379076 A1	12/2014	Vidlund et al.
2013/0245742 A1	9/2013	Norris	2015/0018944 A1	1/2015	O'Connor et al.
2013/0253543 A1	9/2013	Rolando et al.	2015/0032205 A1	1/2015	Matheny
2013/0253643 A1	9/2013	Rolando et al.	2015/0045880 A1	2/2015	Hacohen
2013/0261737 A1	10/2013	Costello	2015/0045881 A1	2/2015	Lim
2013/0261738 A1	10/2013	Clague et al.	2015/0094802 A1	4/2015	Buchbinder et al.
2013/0274870 A1	10/2013	Lombardi et al.	2015/0119970 A1	4/2015	Nakayama et al.
2013/0282059 A1	10/2013	Ketai et al.	2015/0127097 A1	5/2015	Neumann et al.
2013/0289711 A1	10/2013	Liddy et al.	2015/0142100 A1	5/2015	Morriss et al.
2013/0289740 A1	10/2013	Liddy et al.	2015/0142103 A1	5/2015	Vidlund
2013/0297013 A1	11/2013	Klima et al.	2015/0157457 A1	6/2015	Hacohen
2013/0304197 A1	11/2013	Buchbinder et al.	2015/0157458 A1	6/2015	Thambar et al.
2013/0304200 A1	11/2013	McLean et al.	2015/0164640 A1	6/2015	McLean et al.
2013/0310928 A1	11/2013	Morriss et al.	2015/0173896 A1*	6/2015	Richter ..... A61F 2/2427 623/2.11
2013/0325114 A1	12/2013	McLean et al.	2015/0173897 A1	6/2015	Raanani et al.
2013/0331929 A1	12/2013	Mitra et al.	2015/0196390 A1	7/2015	Ma et al.
2014/0000112 A1	1/2014	Braido et al.	2015/0196393 A1	7/2015	Vidlund et al.
2014/0005778 A1	1/2014	Buchbinder et al.	2015/0216661 A1	8/2015	Hacohen et al.
2014/0018911 A1	1/2014	Zhou et al.	2015/0238313 A1	8/2015	Spence et al.
2014/0018915 A1	1/2014	Biadillah et al.	2015/0245934 A1	9/2015	Lombardi et al.
2014/0031928 A1	1/2014	Murphy et al.	2015/0272730 A1*	10/2015	Melnick ..... A61F 2/2433 623/2.11
2014/0046430 A1	2/2014	Shaw	2015/0272731 A1	10/2015	Racchini et al.
2014/0052237 A1	2/2014	Lane et al.	2015/0272734 A1	10/2015	Sheps et al.
2014/0067050 A1	3/2014	Costello et al.	2015/0282964 A1	10/2015	Beard et al.
2014/0067054 A1	3/2014	Chau	2015/0320556 A1	11/2015	Levi et al.
2014/0081376 A1	3/2014	Burkart et al.	2015/0327994 A1*	11/2015	Morriss ..... A61F 2/246 623/2.17
2014/0106951 A1	4/2014	Brandon	2015/0328000 A1	11/2015	Ratz et al.
2014/0120287 A1	5/2014	Jacoby et al.	2015/0335429 A1	11/2015	Morriss et al.
2014/0121749 A1	5/2014	Roeder	2015/0342736 A1	12/2015	Rabito et al.
2014/0121763 A1	5/2014	Duffy et al.	2015/0351903 A1	12/2015	Morriss et al.
2014/0135894 A1	5/2014	Norris et al.	2015/0351904 A1	12/2015	Cooper et al.
2014/0135895 A1	5/2014	Andress et al.	2015/0351906 A1	12/2015	Hammer et al.
2014/0142681 A1	5/2014	Norris	2015/0359629 A1	12/2015	Ganesan et al.
2014/0142688 A1	5/2014	Duffy et al.	2016/0008129 A1	1/2016	Siegel
2014/0148891 A1	5/2014	Johnson	2016/0030169 A1	2/2016	Shahriari
2014/0163690 A1	6/2014	White	2016/0030171 A1	2/2016	Quijano et al.
2014/0172069 A1	6/2014	Roeder et al.	2016/0089482 A1	3/2016	Siegenthaler
2014/0172077 A1	6/2014	Bruchman et al.	2016/0095700 A1	4/2016	Righini
2014/0172082 A1	6/2014	Bruchman et al.	2016/0100939 A1	4/2016	Armstrong et al.
2014/0188210 A1	7/2014	Beard et al.	2016/0106539 A1	4/2016	Buchbinder et al.
2014/0188221 A1	7/2014	Chung et al.	2016/0113766 A1	4/2016	Ganesan et al.
2014/0194981 A1	7/2014	Menk et al.	2016/0113768 A1	4/2016	Ganesan et al.
2014/0194983 A1	7/2014	Kovalsky et al.	2016/0125160 A1	5/2016	Heneghan et al.
2014/0207231 A1*	7/2014	Hacohen ..... A61F 2/2427 623/2.11	2016/0157862 A1	6/2016	Hernandez et al.
			2016/0175095 A1	6/2016	Dienno et al.



(56)

References Cited

U.S. PATENT DOCUMENTS

2016/0213473 A1 7/2016 Hacoheh et al.  
 2016/0220367 A1 8/2016 Barrett  
 2016/0228247 A1 8/2016 Maimon et al.  
 2016/0242902 A1 8/2016 Morriss et al.  
 2016/0270911 A1 9/2016 Ganesan et al.  
 2016/0296330 A1 10/2016 Hacoheh  
 2016/0310268 A1 10/2016 Oba et al.  
 2016/0310274 A1 10/2016 Gross et al.  
 2016/0317301 A1 11/2016 Quadri et al.  
 2016/0317305 A1 11/2016 Pelled et al.  
 2016/0324633 A1 11/2016 Gross et al.  
 2016/0324635 A1 11/2016 Vidlund et al.  
 2016/0324640 A1 11/2016 Gifford et al.  
 2016/0331526 A1 11/2016 Schweich et al.  
 2016/0331527 A1 11/2016 Vidlund et al.  
 2016/0338706 A1 11/2016 Rowe  
 2016/0367360 A1 12/2016 Cartledge et al.  
 2016/0367368 A1 12/2016 Vidlund et al.  
 2016/0374801 A1 12/2016 Jimenez et al.  
 2016/0374802 A1 12/2016 Levi et al.  
 2017/0042678 A1 2/2017 Ganesan et al.  
 2017/0049435 A1 2/2017 Sauer et al.  
 2017/0056166 A1 3/2017 Ratz et al.  
 2017/0056171 A1 3/2017 Cooper et al.  
 2017/0065407 A1 3/2017 Hacoheh et al.  
 2017/0065411 A1 3/2017 Grundeman et al.  
 2017/0100236 A1 4/2017 Robertson et al.  
 2017/0128205 A1 5/2017 Tamir et al.  
 2017/0135816 A1 5/2017 Lashinski et al.  
 2017/0189174 A1 7/2017 Braido et al.  
 2017/0196688 A1 7/2017 Christianson et al.  
 2017/0196692 A1 7/2017 Kirk et al.  
 2017/0209264 A1 7/2017 Chau et al.  
 2017/0216026 A1 8/2017 Quill et al.  
 2017/0224323 A1 8/2017 Rowe et al.  
 2017/0231757 A1 8/2017 Gassler  
 2017/0231759 A1 8/2017 Geist et al.  
 2017/0231760 A1 8/2017 Lane et al.  
 2017/0231766 A1 8/2017 Hariton et al.  
 2017/0239048 A1 8/2017 Goldfarb et al.  
 2017/0252159 A1 9/2017 Hacoheh et al.  
 2017/0266003 A1 9/2017 Hammer et al.  
 2017/0333183 A1 11/2017 Backus  
 2017/0333187 A1 11/2017 Hariton et al.  
 2017/0360426 A1 12/2017 Hacoheh et al.  
 2017/0367823 A1 12/2017 Hariton et al.  
 2018/0000580 A1 1/2018 Wallace et al.  
 2018/0014930 A1 1/2018 Hariton et al.  
 2018/0014932 A1 1/2018 Hammer et al.  
 2018/0021129 A1 1/2018 Peterson et al.  
 2018/0028215 A1 2/2018 Cohen  
 2018/0049873 A1 2/2018 Manash et al.  
 2018/0055628 A1 3/2018 Patel et al.  
 2018/0055630 A1 3/2018 Patel et al.  
 2018/0098850 A1 4/2018 Rafiee et al.  
 2018/0116790 A1 5/2018 Ratz et al.  
 2018/0132999 A1 5/2018 Perouse  
 2018/0147059 A1 5/2018 Hammer et al.  
 2018/0153687 A1 6/2018 Hariton et al.  
 2018/0153689 A1 6/2018 Maimon et al.  
 2018/0161159 A1 6/2018 Lee et al.  
 2018/0177594 A1 6/2018 Patel et al.  
 2018/0206983 A1 7/2018 Noe et al.  
 2018/0214263 A1 8/2018 Rolando et al.  
 2018/0243086 A1 8/2018 Barbarino et al.  
 2018/0250126 A1 9/2018 O'connor et al.  
 2018/0250147 A1 9/2018 Syed  
 2018/0296333 A1 10/2018 Dixon et al.  
 2018/0296336 A1 10/2018 Cooper et al.  
 2018/0296341 A1 10/2018 Noe et al.  
 2018/0325671 A1 11/2018 Abunassar et al.  
 2018/0344457 A1 12/2018 Gross et al.  
 2018/0344490 A1 12/2018 Fox et al.  
 2018/0353294 A1 12/2018 Calomeni et al.  
 2018/0360457 A1 12/2018 Ellis et al.

2019/0000613 A1 1/2019 Delgado et al.  
 2019/0015200 A1 1/2019 Delgado et al.  
 2019/0021852 A1 1/2019 Delgado et al.  
 2019/0021857 A1 1/2019 Hacoheh et al.  
 2019/0053896 A1 2/2019 Adamek-bowers et al.  
 2019/0060060 A1 2/2019 Chau et al.  
 2019/0060068 A1 2/2019 Cope et al.  
 2019/0060070 A1 2/2019 Groothuis et al.  
 2019/0069997 A1 3/2019 Ratz et al.  
 2019/0083261 A1 3/2019 Perszyk et al.  
 2019/0105153 A1 4/2019 Barash et al.  
 2019/0117391 A1 4/2019 Humair  
 2019/0167423 A1 6/2019 Hariton et al.  
 2019/0175339 A1 6/2019 Vidlund  
 2019/0175342 A1 6/2019 Hariton et al.  
 2019/0183639 A1 6/2019 Moore  
 2019/0183644 A1 6/2019 Hacoheh  
 2019/0192295 A1 6/2019 Spence et al.  
 2019/0216602 A1 7/2019 Lozonschi  
 2019/0321172 A1 10/2019 Gross et al.  
 2019/0336280 A1 11/2019 Naor  
 2019/0350701 A1 11/2019 Adamek-bowers et al.  
 2019/0365530 A1 12/2019 Hoang et al.  
 2019/0388218 A1 12/2019 Vidlund et al.  
 2019/0388220 A1 12/2019 Vidlund et al.  
 2020/0000449 A1 1/2020 Goldfarb et al.  
 2020/0000579 A1 1/2020 Manash et al.  
 2020/0015964 A1 1/2020 Noe et al.  
 2020/0060818 A1 2/2020 Geist et al.  
 2020/0078002 A1 3/2020 Hacoheh et al.  
 2020/0163761 A1 5/2020 Hariton et al.  
 2020/0246140 A1 8/2020 Hariton et al.  
 2020/0261094 A1 8/2020 Goldfarb et al.  
 2020/0330221 A1 10/2020 Hacoheh  
 2020/0330227 A1 10/2020 Hacoheh  
 2021/0093449 A1 4/2021 Hariton et al.  
 2021/0106419 A1 4/2021 Abunassar  
 2021/0113331 A1 4/2021 Quadri et al.  
 2021/0137680 A1 5/2021 Kizuka et al.  
 2021/0259835 A1 8/2021 Tyler, II et al.  
 2022/0000612 A1 1/2022 Hacoheh

FOREIGN PATENT DOCUMENTS

EP 0170262 2/1986  
 EP 1264582 12/2002  
 EP 1768630 1/2015  
 EP 2739214 10/2018  
 EP 3417813 12/2018  
 JP S53152790 12/1978  
 KR 20010046894 6/2001  
 WO 1998/043557 10/1998  
 WO 1999/030647 6/1999  
 WO 2000047139 8/2000  
 WO 2001062189 8/2001  
 WO 01/82832 11/2001  
 WO 2003/020179 3/2003  
 WO 2003/028558 4/2003  
 WO 2004/108191 12/2004  
 WO 2005/107650 11/2005  
 WO 2006/007401 1/2006  
 WO 06/054930 5/2006  
 WO 2006/070372 7/2006  
 WO 2006/086434 8/2006  
 WO 2006/089236 8/2006  
 WO 2006/116558 11/2006  
 WO 2006/128193 11/2006  
 WO 2007/059252 5/2007  
 WO 08/013915 1/2008  
 WO 2008/029296 3/2008  
 WO 2008/070797 6/2008  
 WO 2008/103722 8/2008  
 WO 09/033469 3/2009  
 WO 09/053497 4/2009  
 WO 2009/091509 7/2009  
 WO 2010/005827 1/2010  
 WO 2010/006627 1/2010  
 WO 2010/037141 4/2010  
 WO 2010/045297 4/2010



(56)

## References Cited

## FOREIGN PATENT DOCUMENTS

WO	2010/057262	5/2010
WO	2010/073246	7/2010
WO	2010/081033	7/2010
WO	2010/121076	10/2010
WO	2011/025972	3/2011
WO	2011/069048	6/2011
WO	2011/089601	7/2011
WO	2011/106137	9/2011
WO	2011/111047	9/2011
WO	01/87190	11/2011
WO	2011/137531	11/2011
WO	2011/143263	11/2011
WO	2011/154942	12/2011
WO	2012/011108	1/2012
WO	2012/024428	2/2012
WO	2012/036740	3/2012
WO	2012/048035	4/2012
WO	2012/127309	9/2012
WO	2012/177942	12/2012
WO	2013/021374	2/2013
WO	2013/021375	2/2013
WO	2013021384	2/2013
WO	2013/059747	4/2013
WO	2013/072496	5/2013
WO	2013/078497	6/2013
WO	2013114214	8/2013
WO	2013/128436	9/2013
WO	2013/175468	11/2013
WO	2014/022124	2/2014
WO	2014/076696	5/2014
WO	2014/115149	7/2014
WO	2014/121280	8/2014
WO	2014/145338	9/2014
WO	2014/164364	10/2014
WO	2014/194178	12/2014
WO	2015/173794	11/2015
WO	2015/191923	12/2015
WO	2016/016899	2/2016
WO	2016/093877	6/2016
WO	2016/125160	8/2016
WO	2017/223486	12/2017
WO	2018/025260	2/2018
WO	2018/025263	2/2018
WO	2018/029680	2/2018
WO	2018/039631	3/2018
WO	2018/106837	6/2018
WO	2018/112429	6/2018
WO	2018/118717	6/2018
WO	2018/131042	7/2018
WO	2018/131043	7/2018
WO	2019/026059	2/2019
WO	2019/030753	2/2019
WO	2019027507	2/2019
WO	2019/077595	4/2019
WO	2019/116369	6/2019
WO	2019/138400	7/2019
WO	2019/195860	10/2019
WO	2019/202579	10/2019
WO	2020/058972	3/2020
WO	2021/156866	8/2021
WO	2021/186424	9/2021

## OTHER PUBLICATIONS

An Office Action dated Dec. 31, 2012, which issued during the prosecution of U.S. Appl. No. 13/044,694.

An Office Action dated Feb. 6, 2013, which, issued during the prosecution of U.S. Appl. No. 13/412,814.

Langer F et al., "Ring plus String: Papillary muscle repositioning as an adjunctive repair technique for ischemic mitral regurgitation," J Thorac Cardiovasc Surg 133:247-9, Jan. 2007.

Langer F et al., "Ring+String: Successful repair technique for ischemic mitral regurgitation with severe leaflet tethering," Circulation 120[suppl 1 ]: S85-S91, Sep. 2009.

"Transcatheter Valve-in-Valve Implantation for Failed Bioprosthetic Heart Valves", J Webb et al., Circulation. Apr. 2010; 121: 1848-1857.

Jansen, J., Willeke, S., Reul, H. and Rum, G. (1992), Detachable Shape-Memory Sewing Ring for Heart Valves. Artificial Organs, 16:294-297,1992 (an abstract).

Alexander S. Geha, et al., Replacement of degenerated mitral and aortic bioprostheses without explanation Ann Thorac Surg. Jun. 2001; 72:1509-1514.

An International Search Report and a Written Opinion both dated Oct. 13, 2011 which issued during the prosecution of Applicant's PCT/IL11/00231.

An Office Action dated Jul. 1, 2016, which issued during the prosecution of U.S. Appl. No. 14/161,921.

An International Search Report and a Written Opinion both dated Dec. 5, 2011, which issued during the prosecution of Applicant's PCT/IL11/00582.

An Office Action dated May 29, 2012, which issued during the prosecution of U.S. Appl. No. 12/840,463.

U.S. Appl. No. 61/555,160, filed Nov. 3, 2011.

U.S. Appl. No. 61/525,281, filed Aug. 19, 2011.

U.S. Appl. No. 61/537,276, filed Sep. 21, 2011.

U.S. Appl. No. 61/515,372, filed Aug. 5, 2011.

U.S. Appl. No. 61/492,449, filed Jun. 2, 2011.

U.S. Appl. No. 61/588,892, filed Jan. 20, 2012.

An International Search Report and a Written Opinion both dated Feb. 6, 2013, which issued during the prosecution of Applicant's PCT/IL12/00292.

An International Search Report and a Written Opinion both dated Feb. 6, 2013, which issued during the prosecution of Applicant's PCT/IL12/00293.

An Office Action dated Nov. 28, 2012, which issued during the prosecution of U.S. Appl. No. 12/961,721.

An Office Action dated Feb. 15, 2013, which issued during the prosecution of U.S. Appl. No. 12/840,463.

An Office Action dated Feb. 10, 2014, which issued during the prosecution of U.S. Appl. No. 13/033,852.

An Office Action dated Sep. 19, 2014, which issued during the prosecution of U.S. Appl. No. 13/044,694.

An International Search Report and a Written Opinion both dated Sep. 4, 2014 which issued during the prosecution of Applicant's PCT/IL2014/050087.

Invitation to Pay Additional Fees dated Jun. 12, 2014 PCT/IL2014/050087.

An Office Action dated Jun. 17, 2014, which issued during the prosecution of U.S. Appl. No. 12/961,721.

An Office Action dated Jul. 3, 2014, which issued during the prosecution of U.S. Appl. No. 13/033,852.

An Office Action dated May 23, 2014, which issued during the prosecution of U.S. Appl. No. 13/412,814.

Dominique Himbert; Mitral Regurgitation and Stenosis from Bioprosthesis and Annuloplasty Failure: Transcatheter approaches and outcomes, 24 pages Oct. 28, 2013.

An International Search Report and a Written Opinion both dated Mar. 17, 2014 which issued during the prosecution of Applicant's PCT/IL2013/050937.

An International Preliminary Report on patentability dated Dec. 2, 2013, which issued during the prosecution of Applicant's PCT/IL11/00582.

An Office Action dated Sep. 12, 2013, which issued during the prosecution of U.S. Appl. No. 13/412,814.

An Office Action dated Aug. 2, 2013, which issued during the prosecution of U.S. Appl. No. 13/033,852.

An International Preliminary Report on patentability dated Sep. 11, 2012, which issued during the prosecution of Applicant's PCT/IL2011/000231.

An Office Action dated Jul. 2, 2014, which issued during the prosecution of U.S. Appl. No. 13/811,308.

An Office Action dated Jan. 20, 2016, which issued during the prosecution of U.S. Appl. No. 14/161,921.

An Office Action dated Jul. 23, 2013, which issued during the prosecution of U.S. Appl. No. 12/961,721.



(56)

**References Cited**

## OTHER PUBLICATIONS

An Office Action dated Jul. 18, 2013, which issued during the prosecution of U.S. Appl. No. 13/044,694.

An Office Action dated Nov. 8, 2013, which issued during the prosecution of U.S. Appl. No. 12/840,463.

An Office Action dated Jun. 4, 2014, which issued during the prosecution of U.S. Appl. No. U.S. Appl. No. 12/840,463.

An Office Action dated Aug. 13, 2012, which issued during the prosecution of U.S. Appl. No. 13/044,694.

An Office Action dated Jul. 2, 2012, which issued during the prosecution of U.S. Appl. No. 13/033,852.

An Office Action dated Feb. 3, 2014, which issued during the prosecution of U.S. Appl. No. 13/811,308.

An International Preliminary Report on patentability dated Feb. 11, 2014, which issued during the prosecution of Applicant's PCT/IL12/00292.

An International Preliminary Report on patentability dated Feb. 11, 2014, which issued during the prosecution of Applicant's PCT/IL12/00293.

A Notice of Allowance dated Aug. 15, 2014, which issued during the prosecution of U.S. Appl. No. 13/412,814.

An Office Action dated Aug. 14, 2012, which issued during the prosecution of U.S. Appl. No. 12/961,721.

U.S. Appl. No. 61/283,819, filed Dec. 8, 2009.

Notice of Allowance dated Apr. 8, 2016, which issued during the prosecution of U.S. Appl. No. 14/237,258.

U.S. Appl. No. 61/756,034, filed Jan. 24, 2013.

U.S. Appl. No. 61/756,049, filed Jan. 24, 2013.

An International Preliminary Report on Patentability dated Jan. 31, 2017, which issued during the prosecution of Applicant's PCT/IL2015/050792.

U.S. Appl. No. 61/312,412, filed Mar. 10, 2010.

U.S. Appl. No. 62/139,854, filed Mar. 30, 2015.

Notice of Allowance dated Apr. 20, 2018, which issued during the prosecution of U.S. Appl. No. 15/878,206.

An Office Action dated Dec. 10, 2015, which issued during the prosecution of U.S. Appl. No. 14/237,258.

An International Preliminary Report on Patentability dated Jul. 28, 2015, which issued during the prosecution of Applicant's PCT/IL2014/050087.

An Office Action dated Nov. 27, 2015, which issued during the prosecution of U.S. Appl. No. 14/626,267.

An Office Action dated Jan. 21, 2016, which issued during the prosecution of U.S. Appl. No. 14/237,264.

An Office Action dated Jan. 30, 2015, which issued during the prosecution of UK Patent Application No. 1413474.6.

An International Search Report and a Written Opinion both dated May 30, 2016, which issued during the prosecution of Applicant's PCT/IL2016/050125.

An Office Action dated Sep. 26, 2016, which issued during the prosecution of U.S. Appl. No. 14/763,004.

An Office Action dated Jan. 18, 2017, which issued during the prosecution of U.S. Appl. No. 14/626,267.

An Office Action dated Feb. 7, 2017, which issued during the prosecution of U.S. Appl. No. 14/689,608.

An Office Action dated Feb. 8, 2017, which issued during the prosecution of UK Patent Application No. 1613219.3.

An Office Action together dated Feb. 10, 2017, which issued during the prosecution of European Patent Application No. 12821522.5.

An International Search Report and a Written Opinion both dated Oct. 27, 2015, which issued during the prosecution of Applicant's PCT/IL2015/050792.

European Search Report dated Feb. 18, 2015, which issued during the prosecution of Applicant's European App No. 12821522.5.

Saturn Project—a novel solution for transcatheter heart valve replacement specifically designed to address clinical therapeutic needs on mitral valve: Dec. 2016.

Righini presentation EuroPCR. May 2015 (Saturn)—(downloaded from: [Course-videos-slides/2015/Cardiovascularinnovation-pipeline-Mitral-and-tricuspid-valve-interventions\).](https://www.pcronline.com/Cases-resources/images/Resources/</a></p>
</div>
<div data-bbox=)

An Advisory Action dated Apr. 2, 2018, which issued during the prosecution of U.S. Appl. No. 14/763,004.

An Office Action dated Jul. 26, 2018, which issued during the prosecution of U.S. Appl. No. 15/872,501.

An Office Action dated May 4, 2018, which issued during the prosecution of U.S. Appl. No. 15/872,501.

An Office Action dated Apr. 20, 2018, which issued during the prosecution of U.S. Appl. No. 15/886,517.

An Office Action dated Aug. 9, 2018, which issued during the prosecution of U.S. Appl. No. 15/899,858.

An Office Action dated Aug. 9, 2018, which issued during the prosecution of U.S. Appl. No. 15/902,403.

An Office Action dated Jun. 28, 2018, which issued during the prosecution of Design U.S. Appl. No. 29/635,658.

An Office Action dated Jun. 28, 2018, which issued during the prosecution of Design U.S. Appl. No. 29/635,661.

U.S. Appl. No. 62/030,715, filed Jul. 30, 2014.

An Office Action dated Jun. 6, 2018, which issued during the prosecution of UK Patent Application No. 1720803.4.

An International Search Report and a Written Opinion both dated Jun. 20, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050024.

An Office Action dated Jun. 18, 2018, which issued during the prosecution of UK Patent Application No. 1800399.6.

An Office Action dated Oct. 23, 2017, which issued during the prosecution of U.S. Appl. No. 14/763,004.

An Office Action dated Dec. 7, 2017, which issued during the prosecution of U.S. Appl. No. 15/213,791.

Interview Summary dated Feb. 8, 2018, which issued during the prosecution of U.S. Appl. No. 15/213,791.

An Office Action dated Feb. 7, 2018, which issued during the prosecution of U.S. Appl. No. 15/197,069.

An Office Action dated Jan. 5, 2018, which issued during the prosecution of U.S. Appl. No. 15/541,783.

An Office Action dated Feb. 2, 2018, which issued during the prosecution of U.S. Appl. No. 15/329,920.

An Invitation to pay additional fees dated Jan. 2, 2018, which issued during the prosecution of Applicant's PCT/IL2017/050849.

An Invitation to pay additional fees dated Sep. 29, 2017, which issued during the prosecution of Applicant's PCT/IL2017/050873.

European Search Report dated Jun. 29, 2017, which issued during the prosecution of Applicant's European App No. 11809374.9.

An Invitation to pay additional fees dated Oct. 11, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050725.

An Office Action dated Dec. 4, 2018, which issued during the prosecution of U.S. Appl. No. 16/045,059.

An Office Action together with the English translation dated Nov. 5, 2018 which issued during the prosecution of Chinese Patent Application No. 201680008328.5.

Notice of Allowance dated Sep. 25, 2018, which issued during the prosecution of U.S. Appl. No. 15/188,507.

European Search Report dated Sep. 26, 2018 which issued during the prosecution of Applicant's European App No. 18186784.7.

An Office Action dated Jun. 30, 2015, which issued during the prosecution of U.S. Appl. No. 14/522,987.

An Office Action dated Sep. 29, 2017, which issued during the prosecution of U.S. Appl. No. 15/197,069.

Notice of Allowance dated Oct. 30, 2018, which issued during the prosecution of U.S. Appl. No. 15/197,069.

An Office Action dated Jan. 17, 2018, which issued during the prosecution of U.S. Appl. No. 14/763,004.

An Office Action dated Mar. 25, 2015, which issued during the prosecution of U.S. Appl. No. 12/840,463.

An Office Action dated Feb. 25, 2016, which issued during the prosecution of U.S. Appl. No. 14/522,987.

An Office Action dated Apr. 13, 2016, which issued during the prosecution of U.S. Appl. No. 14/626,267.

An Office Action dated Aug. 28, 2015, which issued during the prosecution of U.S. Appl. No. 14/237,264.

An Office Action dated Apr. 21, 2017, which issued during the prosecution of U.S. Appl. No. 15/213,791.



(56)

**References Cited**

## OTHER PUBLICATIONS

Maisano (2015) TCR presentation re Cardiovalve.

Notice of Allowance dated Nov. 19, 2018, which issued during the prosecution of U.S. Appl. No. 15/197,069.

Notice of Allowance dated May 10, 2016, which issued during the prosecution of U.S. Appl. No. 14/237,258.

Notice of Allowance dated May 20, 2016, which issued during the prosecution of U.S. Appl. No. 14/237,258.

Notice of Allowance dated Jul. 6, 2017, which issued during the prosecution of U.S. Appl. No. 14/689,608.

Notice of Allowance dated Aug. 18, 2017, which issued during the prosecution of U.S. Appl. No. 14/689,608.

Notice of Allowance dated May 22, 2017, which issued during the prosecution of U.S. Appl. No. 14/689,608.

Notice of Allowance dated Feb. 11, 2015, which issued during the prosecution of U.S. Appl. No. 13/033,852.

Notice of Allowance dated May 5, 2015, which issued during the prosecution of U.S. Appl. No. 12/840,463.

Notice of Allowance dated Mar. 10, 2015, which issued during the prosecution of U.S. Appl. No. 13/811,308.

Notice of Allowance dated Mar. 18, 2020, which issued during the prosecution of U.S. Appl. No. 16/284,331.

An Office Action dated Jan. 14, 2020, which issued during the prosecution of U.S. Appl. No. 16/284,331.

Notice of Allowance dated May 7, 2020, which issued during the prosecution of U.S. Appl. No. 16/637,166.

An International Search Report and a Written Opinion both dated Nov. 9, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050869.

An Office Action dated Jan. 9, 2020, which issued during the prosecution of U.S. Appl. No. 15/600,190.

An International Search Report and a Written Opinion both dated May 13, 2019, which issued during the prosecution of Applicants PCT/IL2018/051350.

An International Search Report and a Written Opinion both dated Apr. 25, 2019, which issued during the prosecution of Applicant's PCT/IL2019/050142.

An International Search Report and a Written Opinion both dated Jan. 25, 2019, which issued during the prosecution of Applicant's PCT/IL2018/051122.

An International Search Report and a Written Opinion both dated Dec. 5, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050725.

An International Preliminary Report on Patentability dated Feb. 12, 2019, which issued during the prosecution of Applicant's PCT/IL2017/050873.

An International Preliminary Report on Patentability dated Feb. 5, 2019, which issued during the prosecution of Applicant's PCT/IL2017/050849.

An Office Action dated Nov. 26, 2019, which issued during the prosecution of U.S. Appl. No. 16/532,945.

An Office Action dated Nov. 1, 2019, which issued during the prosecution of U.S. Appl. No. 15/872,501.

An Office Action dated Mar. 25, 2019, which issued during the prosecution of European Patent Application No. 14710060.6.

An Office Action dated Oct. 25, 2018, which issued during the prosecution of U.S. Appl. No. 14/763,004.

An Office Action dated Mar. 4, 2019, which issued during the prosecution of U.S. Appl. No. 14/763,004.

An Office Action dated Jan. 9, 2019, which issued during the prosecution of U.S. Appl. No. 15/329,920.

An Office Action dated Jan. 30, 2019, which issued during the prosecution of U.S. Appl. No. 15/872,501.

An Office Action dated Feb. 5, 2019, which issued during the prosecution of U.S. Appl. No. 15/899,858.

An Office Action dated May 23, 2019, which issued during the prosecution of U.S. Appl. No. 15/668,659.

An Office Action dated May 1, 2019, which issued during the prosecution of U.S. Appl. No. 15/691,032.

An Office Action dated Jun. 25, 2019, which issued during the prosecution of U.S. Appl. No. 15/329,920.

An Office Action dated Aug. 23, 2019, which issued during the prosecution of U.S. Appl. No. 15/600,190.

An Office Action dated May 16, 2019, which issued during the prosecution of U.S. Appl. No. 15/433,547.

An Office Action dated Aug. 1, 2019, which issued during the prosecution of U.S. Appl. No. 15/668,559.

An Office Action dated Aug. 16, 2019, which issued during the prosecution of U.S. Appl. No. 15/668,659.

An Office Action dated Jun. 19, 2019, which issued during the prosecution of U.S. Appl. No. 15/682,789.

An Office Action dated Jun. 14, 2019, which issued during the prosecution of U.S. Appl. No. 15/703,385.

An Office Action dated Oct. 4, 2019, which issued during the prosecution of U.S. Appl. No. 16/183,140.

An Office Action dated Jun. 13, 2019, which issued during the prosecution of U.S. Appl. No. 16/388,038.

An Office Action dated Sep. 13, 2019, which issued during the prosecution of U.S. Appl. No. 16/460,313.

Notice of Allowance dated Sep. 10, 2020, which issued during the prosecution of U.S. Appl. No. 15/600,190.

An International Search Report and a Written Opinion both dated Jun. 24, 2020, which issued during the prosecution of Applicant's PCT/IL2019/051398.

Sundermann, Simon H., et al. "Feasibility of the Engager\*\*\* aortic transcatheter valve system using a flexible over-the-wire design," *European Journal of Cardio-Thoracic Surgery* 42.4 (2012): e48-e52.

Serruys, P. W., Piazza, N., Cribier, A., Webb, J., Laborde, J. C., & de Jaegere, P. (Eds.). (2009). *Transcatheter aortic valve implantation: tips and tricks to avoid failure*. CRC Press.—Screenshots from Google Books downloaded from: [https://books.google.co.il/books?id=FLzLBQAAQBAJ&lpg=PA198&ots=soqWrDH-y\\_&dq=%20%22Edwards%20SAPIEN%22&lr&pg=PA20#v=onepage&q=%22Edwards%20SAPIEN%22&f=false](https://books.google.co.il/books?id=FLzLBQAAQBAJ&lpg=PA198&ots=soqWrDH-y_&dq=%20%22Edwards%20SAPIEN%22&lr&pg=PA20#v=onepage&q=%22Edwards%20SAPIEN%22&f=false); Downloaded on Jun. 18, 2020.

Tchetche, D. and Nicolas M. Van Mieghem: "New-generation TAVI devices: description and specifications" *EuroIntervention*, 2014, No. 10:U90-U100.

Symetis S.A.: "ACURATE neo™ Aortic Bioprosthesis for Implantation using the ACURATE neo™ TA Transapical Delivery System in Patients with Severe Aortic Stenosis," *Clinical Investigation Plan*, Protocol No. 2015-01, Vs. No. 2, 2015:1-76.

An Office Action dated Jul. 29, 2020, which issued during the prosecution of U.S. Appl. No. 16/269,328.

Notice of Allowance dated Aug. 26, 2020, which issued during the prosecution of U.S. Appl. No. 16/269,328.

An Office Action dated Jul. 14, 2020, which issued during the prosecution of U.S. Appl. No. 16/324,339.

Notice of Allowance dated Aug. 28, 2020, which issued during the prosecution of U.S. Appl. No. 16/324,339.

An Office Action summarized English translation and Search Report dated Jul. 3, 2020, which issued during the prosecution of Chinese Patent Application No. 201780061210.3.

An Office Action dated Aug. 7, 2020, which issued during the prosecution of U.S. Appl. No. 15/668,659.

Notice of Allowance dated Jul. 29, 2020, which issued during the prosecution of U.S. Appl. No. 16/132,937.

Notice of Allowance dated Apr. 24, 2019, which issued during the prosecution of U.S. Appl. No. 16/045,059.

Notice of Allowance dated Mar. 12, 2020, which issued during the prosecution of U.S. Appl. No. 16/460,313.

An International Preliminary Report on Patentability dated Oct. 20, 2020, which issued during the prosecution of Applicant's PCT/IL2019/050142.

An Office Action dated Oct. 5, 2020, which issued during the prosecution of Canadian Patent Application No. 2,973,940.

Notice of Allowance dated Nov. 19, 2020, which issued during the prosecution of U.S. Appl. No. 16/318,025.

An Office Action dated Sep. 24, 2020, which issued during the prosecution of U.S. Appl. No. 16/811,732.

An Office Action summarized English translation and Search Report dated Nov. 25, 2020, which issued during the prosecution of Chinese Patent Application No. 201910449820.1.



(56)

**References Cited**

## OTHER PUBLICATIONS

An Office Action dated Nov. 30, 2020, which issued during the prosecution of U.S. Appl. No. 16/138,129.

Condado, José Antonio, et al. "Percutaneous edge-to-edge mitral valve repair: 2-year follow-up in the first human case." *Catheterization and cardiovascular interventions* 67.2 (2006): 323-325.

An Office Action dated Dec. 24, 2020, which issued during the prosecution of U.S. Appl. No. 16/144,054.

An Office Action dated Feb. 2, 2021, which issued during the prosecution of U.S. Appl. No. 16/811,732.

An Office Action dated Jan. 13, 2021, which issued during the prosecution of European Patent Application No. 15751089.2.

Maisano, F., et al. "The edge-to-edge technique: a simplified method to correct mitral insufficiency." *European journal of cardio-thoracic surgery* 13.3 (1998): 240-246.

Declaration of Dr. Ivan Vesely, Ph.D. in Support of Petition for Inter Partes Review of U.S. Pat. No. 10,226,341—dated Dec. 17, 2020.

Petition for Inter Partes Review of U.S. Pat. No. 10,226,341 and Exhibits 1001-1013—dated Dec. 29, 2020.

An Office Action together with an English summary dated Mar. 3, 2021, which issued during the prosecution of Chinese Patent Application No. 201780047391.4.

Fucci, C., et al. "Improved results with mitral valve repair using new surgical techniques." *European journal of cardio-thoracic surgery* 9.11 (1995): 621-627.

An Office Action dated Sep. 6, 2018, which issued during the prosecution of U.S. Appl. No. 15/213,791.

Declaration of Ivan Vesely, Ph.D., in Support of Petition for Inter Partes Review of U.S. Pat. No. 7,563,267—dated May 29, 2019.

U.S. Appl. No. 60/128,690, filed Apr. 9, 1999.

Batista, Randa JV, et al. "Partial left ventriculectomy to treat end-stage heart disease." *The Annals of thoracic surgery* 64.3 (1997): 634-638.

Beall Jr, Arthur C., et al. "Clinical experience with a dacron velour-covered teflon-disc mitral-valve prosthesis." *The Annals of thoracic surgery* 5.5 (1968): 402-410.

Kalbacher, D., et al. "1000 MitraClip™ procedures: Lessons learnt from the largest single-centre experience worldwide." (2019): 3137-3139.

U.S. Appl. No. 60/613,867, filed Sep. 27, 2004.

Mitral Valve Academic Research Consortium. "Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles A Consensus Document from the Mitral Valve Academic Research Consortium." *Journal of the American College of Cardiology* 66.3 (2015): 278-307.

Notice of Allowance dated Oct. 3, 2019, which issued during the prosecution of U.S. Appl. No. 15/691,032.

Notice of Allowance dated Mar. 29, 2017, which issued during the prosecution of U.S. Appl. No. 14/161,921.

Feldman, Ted, et al. "Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort." *Journal of the American College of Cardiology* 54.8 (2009): 686-694.

Notice of Allowance dated Nov. 21, 2018, which issued during the prosecution of U.S. Appl. No. 15/213,791.

Notice of Allowance dated Jul. 3, 2019, which issued during the prosecution of U.S. Appl. No. 15/691,032.

An Office Action dated Jan. 6, 2020, which issued during the prosecution of U.S. Appl. No. 16/660,231.

Notice of Allowance dated Jan. 13, 2020, which issued during the prosecution of U.S. Appl. No. 15/956,956.

European Search Report dated Mar. 5, 2020 which issued during the prosecution of Applicant's European App No. 17752184.6.

An Office Action dated Dec. 31, 2019, which issued during the prosecution of U.S. Appl. No. 16/183,140.

An Office Action dated Feb. 6, 2020, which issued during the prosecution of U.S. Appl. No. 15/668,659.

European Search Report dated Mar. 4, 2020 which issued during the prosecution of Applicant's European App No. 16706913.7.

Urena, Marina, et al. "Transseptal transcatheter mitral valve replacement using balloon-expandable transcatheter heart valves: a step-by-step approach." *JACC: Cardiovascular Interventions* 10.19 (2017): 1905-1919.

An Office Action dated Mar. 29, 2021, which issued during the prosecution of U.S. Appl. No. 16/738,516.

An Office Action dated Jan. 3, 2020, which issued during the prosecution of U.S. Appl. No. 16/678,355.

Ando, Tomo, et al. "Iatrogenic ventricular septal defect following transcatheter aortic valve replacement: a systematic review." *Heart, Lung and Circulation* 25.10 (2016): 968-974.

Poirier, Nancy C., et al. "A novel repair for patients with atrioventricular septal defect requiring reoperation for left atrioventricular valve regurgitation." *European journal of cardio-thoracic surgery* 18.1 (2000): 54-61.

Petitioner's Reply to Patent Owner's Response dated Jan. 5, 2022 in IPR2021-00383.

Petitioner's Opposition to Patent Owner's Contingent Motion to Amend dated Jan. 5, 2022 in IPR2021-00383.

Decision Granting Institution of Inter Partes Review dated Dec. 10, 2021 in IPR2021-01051 (42 pages total).

Notice of Allowance dated Dec. 7, 2021 in U.S. Appl. No. 17/394,807.

Office Action dated Nov. 4, 2021 in U.S. Appl. No. 17/366,711.

Extended European Search Report dated Oct. 11, 2021 in European Application No. 21176010.3.

Fann et al., "Beating Heart Catheter-Based Edge-to-Edge Mitral Valve Procedure in a Porcine Model", *Circulation*, 2004, vol. 110, pp. 988-993, Cardiovalve Exhibit 2006 (6 pages total).

Feldman et al., "Percutaneous Mitral Leaflet Repair: MitraClip Therapy for Mitral Regurgitation", Informa Healthcare, 2012, CRC Press, pp. 31-44, Cardiovalve Exhibit 2009 (8 pages total).

Feldman et al., "Percutaneous Mitral Valve Repair Using the Edge-to-Edge Technique", *Journal of the American College of Cardiology*, 2005, vol. 46, No. 11, pp. 2134-2140 (7 pages total).

IPR2021-00383 "Patent Owner's Contingent Motion to Amend", dated Oct. 13, 2021 (35 pages total).

IPR2021-00383 "Patent Owner's Response", dated Oct. 13, 2021 (75 pages total).

Maisano et al., "The Evolution From Surgery to Percutaneous Mitral Valve Interventions", *Journal of the American College of Cardiology*, 2011, vol. 58, No. 21, pp. 2174-2182 (9 pages total).

Notice of Allowance dated Sep. 15, 2021 in U.S. Appl. No. 16/135,599.

Office Action dated Oct. 14, 2021 in U.S. Appl. No. 16/680,739.

Office Action dated Oct. 21, 2021 in U.S. Appl. No. 17/306,231.

Office Action dated Oct. 21, 2021 in U.S. Appl. No. 17/335,845.

Office Action dated Sep. 9, 2021 in U.S. Appl. No. 16/768,909.

Second Declaration of Dr. Michael Sacks, Oct. 13, 2021, IPR2021-00383, U.S. Pat. No. 10,226,341, United States Patent and Trademark Office, Before the Patent Trial and Appeal Board, Cardiovalve Exhibit 2014 (28 pages total).

Transcript of Dr. Vesely, Sep. 22, 2021, Case No. IPR2021-00383, U.S. Pat. No. 10,226,341 United States Patent and Trademark Office Before the Patent Trial and Appeal Board, Cardiovalve Exhibit 2010 (170 pages total).

IPR2021-00383 "Petitioners' Authorized Reply to Patent Owner's Preliminary Response", dated May 27, 2021, 9 pages.

Exhibit 1014, "Transcript of proceedings" held May 20, 2021, 15 pages.

Exhibit 1015, "Facilitate", Meriam-Webster.com, <https://www.merriamwebster.com/dictionary/facilitate>, retrieved May 26, 2021, 5 pages.

IPR2021-00383, "Patent Owner's Authorized Surreply to Petitioner's Reply to Patent Owner's Preliminary Response", dated Jun. 4, 2021, 8 pages.

IPR2021-00383, "Institution decision" dated Jul. 20, 2021, 51 pages.

An extended European search report dated Jun. 10, 2021 in application No. 21157988.3.

International Search Report and Written Opinion dated Jul. 12, 2021 from the International Searching Authority in International Application No. PCT/IL2021/050132.



(56)

**References Cited**

## OTHER PUBLICATIONS

An Office Action dated May 4, 2021, which issued during the prosecution of U.S. Appl. No. 16/636,204.

Notice of Allowance dated May 17, 2021, which issued during the prosecution of U.S. Appl. No. 16/138,129.

Petition for Inter Partes Review of U.S. Pat. No. 10,702,385—dated Jun. 4, 2021.

Declaration of Ivan Vesely, Ph.D. In Support of Petition for Inter Partes Review of U.S. Pat. No. 10,702,385—dated Jun. 4, 2021.

An English summary of an Official Action dated Mar. 29, 2021, which issued during the prosecution of Chinese Patent Application No. 201780061210.3.

An International Search Report and a Written Opinion both dated Jan. 28, 2020, which issued during the prosecution of Applicant's PCT/IL2019/051031.

An International Preliminary Report on Patentability dated Mar. 9, 2021, which issued during the prosecution of Applicant's PCT/IL2019/051031.

An Office Action dated May 12, 2021, which issued during the prosecution of Canadian Patent Application No. 2,973,940.

Notice of Allowance dated Jun. 4, 2021, which issued during the prosecution of U.S. Appl. No. 16/802,353.

An Office Action dated Aug. 1, 2022, which issued during the prosecution of European Patent Application No. 18826823.9.

An Office Action dated Aug. 5, 2022, which issued during the prosecution of U.S. Appl. No. 16/760,147.

An Office Action dated Jul. 20, 2022, which issued during the prosecution of U.S. Appl. No. 17/101,787.

An Office Action dated Jul. 27, 2022, which issued during the prosecution of U.S. Appl. No. 16/881,350.

An Office Action dated Sep. 16, 2022, which issued during the prosecution of U.S. Appl. No. 16/135,466.

An Office Action dated Sep. 21, 2022, which issued during the prosecution of U.S. Appl. No. 16/776,581.

An Office Action dated Sep. 8, 2022, which issued during the prosecution of U.S. Appl. No. 16/896,858.

European Search Report dated Sep. 6, 2022 which issued during the prosecution of Applicant's European App No. 22161862.2.

IPR2021-01051 Patent Owner's Sur-Reply To Petitioners' Reply To Preliminary Guidance dated Aug. 23, 2022.

IPR2021-01051 Petitioners' Reply to Preliminary Guidance dated Aug. 2, 2022.

An International Search Report and a Written Opinion both dated May 3, 2022, which issued during the prosecution of Applicant's PCT/IL2021/051433.

An Office Action dated Jul. 8, 2022, which issued during the prosecution of U.S. Appl. No. 16/144,054.

An Office Action dated Jun. 28, 2022, which issued during the prosecution of U.S. Appl. No. 16/135,969.

An Office Action together with an English Summary dated May 7, 2022 which issued during the prosecution of Chinese Patent Application No. 201880058940.2.

Ex Parte Quayle dated May 2, 2022, which issued during the prosecution of U.S. Appl. No. 16/879,952.

IPR2021-00383 Final Written Decision dated Jul. 18, 2022.

IPR2021-01051 Preliminary Guidance Patent Owner's Motion to Amend dated Jun. 24, 2022.

Notice of Allowance dated May 4, 2022, which issued during the prosecution of U.S. Appl. No. 16/680,739.

An Office Action dated Jan. 26, 2022, which issued during the prosecution of U.S. Appl. No. 16/888,210.

Notice of Allowance dated Jan. 31, 2022, which issued during the prosecution of U.S. Appl. No. 17/479,418.

An Office Action dated Mar. 18, 2022, which issued during the prosecution of U.S. Appl. No. 16/746,489.

Notice of Allowance dated Mar. 22, 2022, which issued during the prosecution of U.S. Appl. No. 17/366,711.

Notice of Allowance dated Mar. 4, 2022, which issued during the prosecution of U.S. Appl. No. 16/768,909.

An Office Action dated Dec. 9, 2021, which issued during the prosecution of U.S. Appl. No. 16/135,969.

An Office Action dated Jan. 24, 2022, which issued during the prosecution of U.S. Appl. No. 16/135,466.

An Office Action dated Apr. 11, 2022, which issued during the prosecution of U.S. Appl. No. 17/473,472.

IPR2021-00383 Preliminary Guidance dated Jan. 31, 2022.

Notice of Allowance dated Dec. 29, 2021 in U.S. Appl. No. 17/210,183.

An invitation to pay additional fees dated May 19, 2021, which issued during the prosecution of Applicant's PCT/IL2021/050132.

An Office Action dated Aug. 18, 2021, which issued during the prosecution of U.S. Appl. No. 17/210,183.

Edwards reply to Preliminary Guidance filed Aug. 2, 2022 in IPR2021-01051 (17 pages total).

Cardiovalve's Sur-reply to EDW's Reply to Preliminary Guidance dated Aug. 23, 2022 in IPR2021-01051 (10 pages total).

An Office Action dated Sep. 29, 2022, which issued during the prosecution of U.S. Appl. No. 17/010,886.

An Office Action dated Sep. 29, 2022, which issued during the prosecution of U.S. Appl. No. 16/656,790.

IPR2021-01051 final written decision dated Dec. 6, 2022.

\* cited by examiner



FIG. 1A






FIG. 1B






FIG. 1D




FIG. 1C






FIG. 2A





FIG. 2B



FIG. 2C




FIG. 2D






FIG. 3A









FIG. 3B












FIG. 3G




FIG. 3H

FIG. 3I






FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 4E




FIG. 4F






FIG. 5




FIG. 6A




FIG. 6B






FIG. 7





FIG. 8













FIG. 9B

FIG. 9C





**IMPLANT FOR HEART VALVE****CROSS-REFERENCES TO RELATED APPLICATIONS**

This application is a Continuation of U.S. Ser. No. 17/982, 897 to Gross et al., filed Nov. 8, 2022, which published as US 2023/0058653, which is a Continuation of U.S. Ser. No. 16/888,210 to HaCohen, filed May 29, 2020, now U.S. Pat. No. 11,517,436, which is a Continuation of U.S. Ser. No. 16/284,331 to HaCohen, filed Feb. 25, 2019, now U.S. Pat. No. 10,702,385, which is a Continuation of U.S. Ser. No. 15/197,069 to Gross et al., filed Jun. 29, 2016, now U.S. Pat. No. 10,226,341, which is a Continuation of U.S. Ser. No. 14/237,258 to Gross et al., filed May 23, 2014, now U.S. Pat. No. 9,387,078, which is the US National Phase of PCT Patent Application IL2012/000293 to Gross et al., filed Aug. 5, 2012, which published as WO 2013/021375, and which:

(1) claims priority from:

U.S. 61/515,372 to Gross et al., filed Aug. 5, 2011;  
 U.S. 61/525,281 to Gross et al., filed Aug. 19, 2011;  
 U.S. 61/537,276 to Gross et al., filed Sep. 21, 2011;  
 U.S. 61/555,160 to Gross et al., filed Nov. 3, 2011;  
 U.S. 61/588,892 to Gross et al., filed Jan. 20, 2012; and  
 U.S. Ser. No. 13/412,814 to Gross et al., filed Mar. 6, 2012, now U.S. Pat. No. 8,852,272, all of which are incorporated herein by reference; and

(2) is a continuation-in-part of U.S. Ser. No. 13/412,814 to Gross et al., filed Mar. 6, 2012, now U.S. Pat. No. 8,852,272.

This application is related to PCT application IL2012/000292 to Gross et al., entitled, "Techniques for percutaneous mitral valve replacement and sealing," filed Aug. 5, 2012, which published as WO 2013/021374.

**FIELD OF THE INVENTION**

Some applications of the present invention relate in general to valve replacement. More specifically, some applications of the present invention relate to prosthetic valves for replacement of a cardiac valve.

**BACKGROUND**

Ischemic heart disease causes regurgitation of a heart valve by the combination of ischemic dysfunction of the papillary muscles, and the dilatation of the ventricle that is present in ischemic heart disease, with the subsequent displacement of the papillary muscles and the dilatation of the valve annulus.

Dilation of the annulus of the valve prevents the valve leaflets from fully coapting when the valve is closed. Regurgitation of blood from the ventricle into the atrium results in increased total stroke volume and decreased cardiac output, and ultimate weakening of the ventricle secondary to a volume overload and a pressure overload of the atrium.

**SUMMARY OF THE INVENTION**

For some applications of the invention, a prosthetic valve support is provided for facilitating minimally invasive (e.g., transcatheter and/or transluminal) implantation of a prosthetic valve at a native valve of a subject. The native valve typically has native check valve functionality, i.e., it functions as a check valve. It is understood that a diseased valve has sub-optimal native check valve functionality, however the term "check valve functionality," as used in the context

of the specification and in the claims, when used with respect to a native valve, refers to the native level of check valve functionality of the native valve. The prosthetic valve support is typically couplable to the native valve (e.g., to leaflets thereof) of the subject without eliminating the check valve functionality of the native valve. The prosthetic valve is subsequently implanted at the native valve by coupling the prosthetic valve to the prosthetic valve support, typically by expanding the prosthetic valve within one or more openings defined by the prosthetic valve support. The implantation of the prosthetic valve at the native valve replaces, at least in part, the check valve functionality of the native valve with substitute check valve functionality of the prosthetic valve. The prosthetic valve support comprises tissue-engaging elements, such as clips. Typically, but not necessarily, the prosthetic valve support further comprises (1) an upstream support portion, configured to be placed against an upstream surface of the native valve, and shaped to define one of the openings, and (2) a stabilizing element, shaped to define another of the openings.

For some applications, the prosthetic valve support is configured to be coupled to the native valve (e.g., to leaflets thereof) without eliminating the check valve functionality of the native valve, by allowing (1) the native leaflets to define a single orifice, and (2) the native valve to function as a single check valve (e.g., to function in a manner that is generally similar to the natural (e.g., physiological) function of the native valve). For some applications, the prosthetic valve support is configured to be coupled to the native valve (e.g., to leaflets thereof) without eliminating the check valve functionality by coupling together respective portions of two leaflets, such that (1) the native leaflets define two orifices, and (2) the native valve functions as two (e.g., parallel) check valves.

For some applications, it is hypothesized that the use of a two-component implant (i.e., comprising the prosthetic valve support and a separate prosthetic valve), advantageously facilitates delivery of the prosthetic valve via a catheter narrower than 28 Fr (e.g., by allowing the use of a 'minimalistic' prosthetic valve, such as a prosthetic valve with few or no appendages).

For some applications, it is hypothesized that the use of a prosthetic valve support that does not eliminate check valve functionality of the native valve, facilitates the separate delivery of the prosthetic valve support and the prosthetic valve (i.e., a two-stage delivery), and thereby further facilitates the use of a narrow catheter.

For some applications, it is further hypothesized that the use of the prosthetic valve support enhances the check valve functionality of the native valve, and thereby provides both (1) "repair" of the native valve, and (2) an implantation site that is pre-prepared for subsequent implantation of a prosthetic valve at a later date, should such implantation be subsequently considered necessary.

There is therefore provided, in accordance with an application of the present invention, apparatus for use with a prosthetic valve for implantation at a native valve of a subject, the native valve including at least one native leaflet, the apparatus including:

a prosthetic valve support, including:

an upstream support portion, being configured to be placed against an upstream side of the native valve, and having an inner perimeter that defines an opening that is configured to receive the prosthetic valve, and  
 at least one clip:



3

including at least two clip arms and a clip-controller interface, the clip-controller interface being coupled to at least one of the clip arms, and being configured to be coupled to a native leaflet of the native valve; and

at least one clip controller, reversibly couplable to the clip-controller interface, and configured to facilitate opening and closing of the clip.

In an application, the at least two clip arms include a first clip arm, configured to be disposed against an upstream surface of the leaflet, and a second clip arm, configured to be disposed against a downstream surface of the leaflet.

In an application, the clip controller is configured to facilitate opening and closing of the clip irrespective of a state of expansion of the prosthetic valve support.

In an application, the at least one clip includes at least a first clip and a second clip, and the second clip is openable and closeable independently of the first clip.

In an application, the at least one clip includes at least a first clip and a second clip, and the first clip is fixedly coupled to the second clip, and is configured to be decoupled from the second clip.

In an application, the at least one clip is configured to be coupled to a single native leaflet of the native valve.

In an application, the at least one clip is configured to be lockable such that the first clip arm is locked with respect to the second clip arm.

In an application:

the native valve includes at least a first native leaflet and a second native leaflet,

the at least one clip includes at least a first clip and a second clip, the first clip being configured to be coupled to the first leaflet, and the second clip being configured to be coupled to the second leaflet, and

the prosthetic valve support is configured such that, when (1) the upstream support portion is disposed against the upstream side of the native valve, (2) the first clip is coupled to the first leaflet, and (3) the second clip is coupled to the second leaflet, the first clip moves toward the second clip during ventricular systole of the subject, and moves away from the second clip during ventricular diastole of the subject.

In an application, the clip is flexibly coupled to the upstream support portion.

In an application, the clip is coupled to the upstream support portion via a flexible connector, the flexible connector having a length from the upstream support portion to the clip, and the length of the flexible connector is variable.

In an application, the upstream support portion is generally flat.

In an application, the inner perimeter defines the opening, such that the opening has a depth and a width, and the width of the opening is more than four times greater than the depth of the opening.

In an application, the upstream support portion has a free inner edge, and the free inner edge defines the inner perimeter.

In an application, the inner perimeter defines an opening that has a diameter, and the upstream support portion has a diameter that is at least 10 percent greater than the diameter of the opening.

In an application, no part of the prosthetic valve support that circumscribes a space that has a perimeter greater than 60 mm has a height of more than 20 mm.

There is further provided, in accordance with an application of the present invention, apparatus for facilitating implantation of a prosthetic valve at a native heart valve of

4

a subject, the native heart valve including a native annulus and a plurality of native leaflets that provide check valve functionality, the apparatus including a prosthetic valve support, the prosthetic valve support:

being configured to be transluminally-delivered to the native valve and to be deployed at the native valve, and including one or more tissue-engaging elements, configured to couple the prosthetic valve support to the native leaflets without eliminating the check valve functionality.

In an application, the tissue-engaging elements are configured to couple the prosthetic valve support to the native leaflets without eliminating the check valve functionality, by coupling the prosthetic valve support to the native leaflets such that:

the native leaflets define a single orifice therebetween, and the native valve functions as a single check valve.

In an application, the tissue-engaging elements include at least a first tissue-engaging element and a second tissue-engaging element, and the first tissue-engaging element is transluminally controllable independently of the second tissue-engaging element.

In an application, the tissue-engaging elements are configured to couple the prosthetic valve support to the native leaflets without eliminating the check valve functionality, by coupling the prosthetic valve support to the native leaflets such that:

the native leaflets define two orifices therebetween, and the native valve functions as two check valves.

In an application:

the native leaflets include a first leaflet and a second leaflet,

the tissue-engaging elements include at least a first tissue-engaging element and a second tissue-engaging element,

the first tissue-engaging element is configured to be coupled to a portion of the first leaflet, and

the second tissue-engaging element is configured to be coupled to a portion of the second leaflet and to the first tissue-engaging element.

In an application, the apparatus is configured such that the first tissue-engaging element is transluminally, intracorporeally decouplable from the second tissue-engaging element.

In an application, the prosthetic valve support includes an annular upstream support portion:

shaped to define an opening therethrough,

coupled to the tissue-engaging elements,

configured to be placed against an upstream surface of the native annulus, and

configured to be transluminally, intracorporeally, coupled to the prosthetic valve.

In an application, the apparatus further includes the prosthetic valve, and the prosthetic valve includes a flexible netting at at least an upstream portion of the prosthetic valve, and the netting is configured to facilitate coupling of the prosthetic valve to the upstream support portion.

In an application, the prosthetic valve support includes one or more flexible connectors, and each tissue-engaging element is flexibly coupled to the upstream support portion by a respective flexible connector.

In an application, each flexible connector has a length, and is configured such that the length is variable while the tissue-engaging elements are coupled to the native leaflets.

In an application, the upstream support portion has a compressed configuration and an expanded configuration, and is configured (1) to be delivered to the native valve in



the compressed configuration, and (2) to be expanded into the expanded configuration at the native valve.

In an application, the apparatus further includes one or more coupling leads, and the apparatus is configured such that the expansion of the upstream support portion is controllable using the coupling leads.

In an application, each coupling lead passes around at least a portion of the upstream support portion, and the apparatus is configured such that the upstream support portion is recompressible from the expanded configuration toward the compressed configuration, by pulling on the coupling leads.

In an application, the prosthetic valve support includes a downstream stabilizing element:

shaped to define an opening therethrough,  
coupled to the tissue-engaging elements,  
configured to be placed entirely downstream of the native annulus, and  
configured to be coupled to the prosthetic valve.

In an application, the apparatus further includes the prosthetic valve, and the prosthetic valve includes a valve body and one or more valve-anchoring elements, the valve-anchoring elements being configured to sandwich the downstream stabilizing element between the valve-anchoring elements and the valve body.

In an application, the prosthetic valve support is configured to be coupled to the native leaflets such that no portion of the prosthetic valve support is disposed upstream of the native annulus.

In an application, the tissue-engaging elements include clips, each clip including a plurality of clip arms, including at least a first clip arm and a second clip arm, and configured to couple at least a portion of one of the native leaflets between the first and second clip arms.

In an application, the apparatus further includes a clip controller, configured to be advanced transluminally to the native valve, and each clip includes a clip-controller interface, configured to be reversibly coupled to the clip controller, and to facilitate extracorporeal control of the clips independently of deployment of the prosthetic valve support.

In an application, each clip is configured such that movement of at least a portion of the clip-controller interface by a first distance, changes a distance between a portion of the first clip arm and a portion of the second clip arm by a second distance that is more than 1.5 times greater than the first distance.

In an application, the tissue-engaging elements are configured to suturelessly couple the prosthetic valve support to the native leaflets.

In an application, the prosthetic valve support is configured to be transluminally, intracorporeally, couplable to the prosthetic valve.

There is further provided, in accordance with an application of the present invention, a method for use at a native valve of a subject, the native valve including at least one native leaflet that provides native check valve functionality, the method including:

transluminally delivering a prosthetic valve support to the native valve;  
coupling a prosthetic valve support to the leaflet of the native valve without eliminating the native check valve functionality; and  
subsequently, replacing, at least in part, the native check valve functionality with a substitute check valve functionality, by coupling a prosthetic valve to the prosthetic valve support.

In an application:

the prosthetic valve support includes at least one clip, the clip includes two or more clip arms and a clip-controller interface, and

coupling the prosthetic valve support to the leaflet includes changing an angular disposition between the clip arms by moving the clip-controller interface.

There is further provided, in accordance with an application of the present invention, apparatus for use with a native heart valve of a subject, the apparatus including:

a first expandable prosthetic valve component, including a crimpable frame, and configured to be transcatheterally advanceable toward the native valve while the first prosthetic valve component is in a crimped state thereof,

a second expandable prosthetic valve component, including a crimpable frame, and configured to be transcatheterally advanceable toward the native valve, placeable in the native valve while the second prosthetic valve component is in a crimped state thereof, and couplable to the first prosthetic valve component, expansion of the second prosthetic valve component facilitating coupling of the second prosthetic valve component to the first prosthetic valve component; and

one or more tissue-engagement elements, coupled to at least one of the prosthetic valve components, the tissue-engagement elements configured, when the prosthetic valve component is in an expanded state thereof, to extend from the prosthetic valve component, and to inhibit a proximal movement of the prosthetic valve component.

There is further provided, in accordance with an application of the present invention, apparatus for use with a prosthetic valve for implantation at a native valve of a subject, the native valve (1) defining an orifice, (2) including at least one native leaflet, having a native beating, and (3) having a native blood flow regulation functionality, the apparatus including:

a prosthetic valve support, including:

an upstream support portion, configured to be placed against an upstream side of the native valve, to have an inner perimeter that defines an opening that is configured to receive the prosthetic valve, and

at least one clip, configured to be coupled to a native leaflet of the native valve, the clip including a plurality of clip arms, at least one clip arm coupled to a clip-controller interface; and

a clip controller, couplable to the clip-controller interface, and configured to control a relative angular disposition between the clip arms.

For some applications, techniques described herein are practiced in combination with techniques described in one or more of the references cited in the Background section and Cross-references section of the present patent application.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-D are schematic illustrations of apparatus, comprising a prosthetic valve support, for facilitating implantation of a prosthetic heart valve at a native heart valve of a subject, in accordance with some applications of the invention;

FIGS. 2A-D are schematic illustrations of the prosthetic valve support, and components thereof, in accordance with respective applications of the invention;

FIGS. 3A-I are schematic illustrations of steps in the delivery and implantation of the prosthetic valve support at



the native heart valve of the subject, and the use thereof to facilitate implantation of the prosthetic valve, in accordance with some applications of the invention;

FIGS. 4A-F are schematic illustrations of a system for facilitating controlled expansion and/or retrievability of an upstream support portion of the prosthetic valve support, in accordance with some applications of the invention;

FIG. 5 is a schematic illustration of a step in the implantation of the prosthetic valve support, in accordance with some applications of the invention;

FIGS. 6A-B are schematic illustrations of a prosthetic valve support comprising tissue-engaging elements that are couplable to each other, and decouplable from each other, in accordance with some applications of the invention;

FIG. 7 is a schematic illustration of a prosthetic valve support comprising the upstream support portion and three clips, in accordance with some applications of the invention;

FIG. 8 is a schematic illustration of a step in the implantation of the prosthetic valve, facilitated by the prosthetic valve support, in accordance with some applications of the invention; and

FIGS. 9A-C are schematic illustrations of the prosthetic valve support comprising variable-length connectors, in accordance with respective applications of the invention.

#### DETAILED DESCRIPTION OF EMBODIMENTS

Reference is made to FIGS. 1A-D, which are schematic illustrations of apparatus 20, comprising a prosthetic valve support 22 for facilitating implantation of a prosthetic heart valve at a native heart valve of a subject, in accordance with some applications of the invention. Prosthetic valve support 22 comprises one or more tissue-engaging elements 24 (e.g., support-anchoring elements), and is typically configured to be coupled to the native heart valve (e.g., to leaflets thereof) without eliminating check valve functionality of the native heart valve (described in more detail hereinbelow). Typically, prosthetic valve support 22 is configured to be transluminally, intracorporeally coupled to the native heart valve.

Typically, each tissue-engaging element 24 comprises a clip 30, which typically comprises a plurality of clip arms 32 (e.g., two clip arms, e.g., a first clip arm 32a and a second clip arm 32b), the clip being configured to be coupled to a leaflet of the native valve. Clip arms 32a and 32b are movable with respect to each other, thereby opening and closing clip 30 (e.g., moving clip 30 between an open state and a closed state thereof), e.g., as shown in FIG. 1B. Clip arms 32a and 32b are typically articulatably coupled to each other at an articulation point 31 (e.g., a coupling point), such that opening and closing clip 30 comprises changing a relative angular disposition between the clip arms. Typically, each clip arm 32 has a length from a first end thereof, at which the clip arms are coupled to each other (e.g., at articulation point 31), to a second end thereof, of greater than 1.5 mm and/or less than 20 mm (e.g., between 3 and 10 mm). For some applications, a length d7 of clip arm 32a is generally the same as a length d8 of clip arm 32b (e.g., as shown in FIG. 1B). For some applications, length d8 of clip arm 32b is shorter than length d7 of clip arm 32a (e.g., at least 30% shorter, such as at least 50% shorter), e.g., so as to reduce force applied to the leaflet of the native valve by clip arm 32b (such as by the second end of the clip arm).

For some applications of the invention, at least one of the clip arms (e.g., clip arm 32b) comprises a tissue-engaging portion 48 that is articulatably coupled to another portion of the clip arm at an articulation point 47, such that, at a given relative angular disposition of clip arms 32a and 32b (e.g.,

a degree of openness of clip 30), a relative angular disposition of portion 48 with respect to clip arm 32a, may change (e.g., may be changed). For example, for at least some states of clip 30, the relative angular disposition of clip arm 32a and portion 48 may be generally independent of the relative angular disposition of clip arm 32a and the other portion of clip arm 32b. For example, portion 48 may remain parallel with clip arm 32a, irrespective of the angular disposition of clip arms 32a and 32b. It is hypothesized that this configuration facilitates coupling of clip 30 to the leaflet of the native valve, by allowing the clip to maintain contact with both sides of the leaflet, irrespective of dimensions (e.g., thicknesses) of the leaflet to which clip 30 is coupled.

Prosthetic valve support 22 is typically configured to be implanted using minimally-invasive procedures (e.g., percutaneously). Further typically, the prosthetic valve support is configured to be delivered transluminally (e.g., transfemorally). Alternatively, the prosthetic valve support may be configured to be delivered transthoracically (e.g., transapically). Typically, the prosthetic valve support is configured in this way by being compressible (e.g., crimpable) into a delivery configuration, and by being configured to expand (e.g., automatically) upon deployment at the native valve. Typically, tissue-engaging elements 24 (e.g., clips 30) are coupled to the leaflets of the native valve before prosthetic valve support 22 is fully deployed, such as while at least part of the prosthetic valve support remains within a delivery tube (e.g., as shown in FIGS. 3B-C).

Clips 30 are typically configured to be controllable (i.e., openable and closable) independently of each other, and/or independently of deployment of prosthetic valve support 22 (e.g., irrespective of a state of deployment of the prosthetic valve support, such as irrespective of a state of expansion of an upstream support portion 60 of the prosthetic valve support, described hereinbelow).

Clip 30 typically further comprises a clip-controller interface 34, which is configured to facilitate control (e.g., opening and closing) of the clip from outside the subject (i.e., to facilitate extracorporeal control of the clip), e.g., by a physician. Clip-controller interface 34 is reversibly couplable to a clip controller 36, which is itself extracorporeally controllable, e.g., by extending from outside the subject to the clip-controller interface. Clip 30 is thereby typically transluminally controllable. Typically, clip controller 36 facilitates control of the clip by applying a force to clip-controller interface 34, e.g., by transferring an extracorporeally-applied force to the clip-controller interface. Typically, clip controller 36 is integral with delivery apparatus that is used to deliver support 22 to the native valve (e.g., delivery apparatus 140, described hereinbelow with reference to FIGS. 3A-D).

Clip-controller interface 34 is typically articulatably coupled to at least clip arm 32b (e.g., at an articulation point 35), and/or comprises one or more articulatably coupled portions (e.g., a first interface portion 34a and a second interface portion 34b). Clips 30 are typically configured such that movement of clip-controller interface 34 by a first distance d1, moves clip arm 32b by a second distance d2 that is typically more than 1.5 times (e.g., more than 2 times, such as more than 4 times) greater than distance d1. That is, a relatively large range of movement of clip arm 32b is provided by a relatively small range of movement of clip-controller interface 34, e.g., clip-controller interface 34, clip arm 32b, and/or the coupling therebetween, acts as a lever. Clip 30 is typically configured such that clip arm 32b can articulate over more than 60 degrees, e.g., more than 100



degrees, such as up to 180 degrees, around articulation point **31**, with respect to clip arm **32a**.

It is hypothesized that, for some applications, angles of articulation greater than 80 degrees (e.g., greater than 120 degrees, such as up to 180 degrees) facilitate (1) repeated coupling to, and decoupling from, the native leaflets (e.g., multiple attempts to couple to the native leaflets), and (2) retrieval of the clips and/or the entire prosthetic valve support (e.g., into a delivery tube).

Clip-controller interface **34** (e.g., portion **34a** thereof) is typically slidably coupled to at least clip arm **32a**. That is, moving of clip-controller interface **34** typically includes sliding of the clip-controller interface with respect to clip arm **32a** (e.g., by using clip controller **36**).

For some applications of the invention, at least one of clip arms **32** comprises or defines grips **38** and/or teeth **40**, which are configured to facilitate coupling of clip **30** to a native leaflet of the native valve. Typically, grips **38** are configured to atraumatically grip the leaflet and teeth **40** are configured to grip, fold around, and/or pierce the leaflet. For some applications of the invention, at least a portion of clip arms **32** is covered with a padding (not shown), configured to cushion the contact between the clip arms and the leaflet.

Typically, clip **30** is lockable, such that clip arm **32b** is locked (e.g., immobile) with respect to clip arm **32a**. FIGS. **1B-D** show clip **30** comprising a locking element **50** (e.g., a securing element), which facilitates locking of the clip. Locking element **50** typically comprises at least one ratchet mechanism **52**, comprising (1) a rack **51**, comprising a plurality of sockets **54**, and (2) an engaging element **56** (e.g., a pawl, or a tooth). Typically, rack **51** is defined by, or is fixedly coupled to, clip arm **32a**, and engaging element **56** is coupled to, or defined by, clip-controller interface **34**. However, the scope of the invention includes other (e.g., inverse) arrangements of ratchet mechanism **52**.

FIG. **1B** shows clip **30** in an unlocked configuration thereof, in which an obstructing element **58** (e.g., a restraint) is disposed between rack **51** and engaging element **56**, thereby inhibiting (e.g., obstructing) engaging element **56** from engaging rack **51**, and thereby facilitating the opening and closing of the clip (i.e., movement between open and closed states thereof). Typically, obstructing element **58** is integral with delivery apparatus that is used to deliver support **22** to the native valve (e.g., delivery apparatus **140**, described hereinbelow with reference to FIGS. **3A-D**). FIG. **1B** shows a front view and a back view of clip **30** in the open state thereof, and a front view and a back view of the clip in the closed state thereof.

FIG. **1C** shows a back view of clip **30** in a locked configuration thereof, in which obstructing element **58** has been removed from between rack **51** and engaging element **56** (e.g., by withdrawing the obstructing element proximally), and an engaging element **56** has engaged the rack. Typically, element **56** is configured (e.g., shape-set) to automatically engage rack **51** upon removal of obstructing element **58**.

For some applications, and as shown in FIGS. **1B-D**, obstructing element **58** comprises a longitudinal member, such as a strip or rod, and is removed by being withdrawn proximally. However, obstructing element **58** may have other shapes and/or shape-memory features that facilitate the obstruction of engaging element **56** and/or the removal of the obstructing element. For example, obstructing element **58** may have a generally circular, rectangular, triangular, or hexagonal cross-section, and/or may be shape-set to facilitate removal thereof, and thereby to facilitate locking of the clip.

For some applications of the invention, and as shown in FIGS. **1B-D**, locking element **50** comprises two ratchet mechanisms **52**. The two ratchet mechanisms are offset with respect to the other, such that at a position of clip-controller interface **34** in which the engaging element **56** of one ratchet mechanism is fully disposed in a socket **54**, the engaging element of the other ratchet mechanism is not fully disposed in a socket of the other rack (FIGS. **1C-D**). This configuration increases (e.g., doubles) the number of positions within a given range in which clip-controller interface **34** is lockable, without reducing the size of each socket **54**. That is, this configuration increases the “resolution” or “density” of locking positions of clip **30**. It is hypothesized that, for some applications, it is advantageous to combine this configuration of locking element **50** with the lever-like clip-controller interface described hereinabove, such that the relatively large movement of clip arm **32b** is at least partly offset by the “high resolution” of the locking element, thereby increasing the degree of control that the physician has on the clip.

As described hereinabove, clip-controller interface **34** is typically reversibly couplable to clip controller **36**. Typically, this reversible coupling is facilitated by a projection **42**, defined by clip controller **36**, which is configured to be disposed within, and removed from, a depression **44**, defined by clip-controller interface **34**. Further typically, projection **42** is configured (e.g., shape-set) to move out from depression **44**, and is prevented from moving out of depression **44** by obstructing element **58**. Following the locking of clip **30** by withdrawing obstructing element **58** (FIG. **1C**), the obstructing element is further withdrawn (FIG. **1D**), thereby releasing projection **42** from depression **44**, and thereby decoupling clip controller **36** from clip-controller interface **34**. Clip **30** is typically configured such that the physician may repeatedly lock and unlock clip **30** (e.g., by partially withdrawing and replacing obstructing element **58**) before finally decoupling the controller (e.g., by completely withdrawing obstructing element **58**), such as after confirming that clip **30** has been successfully coupled to the native leaflet.

As described hereinabove, clips **30** are typically configured to be controllable (i.e., openable and closable) independently of each other, and/or independently of deployment of prosthetic valve support **22**. Clips **30** are further typically lockable and/or decouplable from controller **36** independently of each other, and/or independently of deployment of the prosthetic valve support. It is to be noted that clips **30** are configured to couple the prosthetic valve support to the native leaflets suturelessly.

Referring again to FIG. **1A**, prosthetic valve support **22** typically comprises a generally annular upstream support portion **60** (e.g., an annular portion), shaped to define an opening **61** (e.g., an aperture) therethrough, and to be placed against an upstream side of the native valve. Typically, upstream support portion **60** comprises an expandable lattice-structure frame **62** (e.g., comprising a plurality of struts), covered by a covering **64**. Opening **61** is defined by an inner perimeter **68** of the prosthetic valve support. For some applications, frame **62** defines a plurality of barbs **67** that protrude radially inwardly from inner perimeter **68**, and facilitate coupling of a prosthetic valve to the prosthetic valve support (e.g., as described hereinbelow with reference to FIGS. **3H-I**).

Upstream support portion **60** typically has shape-memory (e.g., resilient, pseudoelastic and/or superelastic) properties. Typically, frame **62** comprises a shape-memory (e.g., resilient, pseudoelastic and/or superelastic) material, such that



## 11

upstream support portion **60** is compressible (e.g., crimpable) when a compressive force is applied (e.g., prior to implantation), and re-expandable when the compressive force is removed (e.g., during implantation). Non-limiting examples of materials that frame **62** may comprise, include nickel-titanium (nitinol), stainless steel, nickel cobalt, cobalt chrome, titanium, tantalum, and palladium.

Non-limiting examples of materials that covering **64** may comprise, include polyethylene terephthalate (e.g., polyester), polytetrafluoroethylene (e.g., Teflon, ePTFE), and pericardial tissue. For some applications, covering **64** comprises a fabric. Typically, a thickness of the covering is less than 0.5 mm, such as less than 0.2 mm, e.g., less than 0.1 mm, or less than 0.05 mm.

FIG. 1A shows upstream support portion **60** in an expanded (e.g., fully uncompressed and/or deployed) configuration thereof, in which upstream support portion **60** (i.e., an outer perimeter **69** thereof) typically has a diameter  $d_3$  that is greater than 40 mm and/or less than 80 mm (e.g., 40-80 mm, such as 40-70 mm, such as 40-60 mm). That is, an outer diameter of upstream support portion **60** is typically greater than 40 mm and/or less than 80 mm (e.g., 40-80 mm, such as 40-70 mm, such as 40-60 mm). Opening **61**, defined by inner perimeter **68**, typically has a diameter  $d_4$  of greater than 20 mm and/or less than 35 mm (e.g., 20-35 mm, such as 23-32 mm, such as 25-30 mm). That is, an inner diameter of upstream support portion **60** is typically greater than 20 mm and/or less than 35 mm (e.g., 20-35 mm, such as 23-32 mm, such as 25-30 mm). Typically, diameter  $d_3$  is at least 10% (e.g., at least 50%, such as at least 80%) greater than diameter  $d_4$ .

Upstream support portion **60** is typically compressible (e.g., crimpable; for delivery to the native valve) into a generally cylindrical shape in which inner perimeter **68** defines a downstream end **71** of the cylindrical shape, and outer perimeter **69** defines an upstream end **73** of the cylindrical shape (see FIG. 3A). Typically, the generally cylindrical shape of upstream support portion **60** has a transverse cross-sectional diameter (e.g., a width) of greater than 3 mm and/or less than 9 mm (e.g., 3-9 mm, such as 5-8 mm, such as 6-7 mm), and a height, from the upstream end to the downstream end, of greater than 11 mm and/or less than 30 mm (e.g., 11-30 mm, such as 15-30 mm, such as 15-25 mm).

In the expanded configuration thereof, upstream support portion **60** is typically (but not necessarily) generally flat (e.g., laminar, and/or planar). For some applications, in the expanded configuration, upstream support portion **60** assumes a frustoconical shape. Upstream support portion **60** typically has a thickness of less than 5 mm, e.g., less than 2 mm, such as between 0.3 mm and 2 mm. Inner perimeter **68** (and thereby opening **61**) thereby typically has a depth  $d_{10}$  (e.g., a height) from an upstream side **59** of the upstream support portion to a downstream side **63** of the upstream support portion. Depth  $d_{10}$  is less than 5 mm, e.g., less than 2 mm, such as between 0.3 mm and 2 mm. Typically, diameter  $d_4$  of opening **61** is more than 4 times (e.g., more than 6 times, such as more than 10 times) greater than depth  $d_{10}$ . That is, opening **61** is more than 4 times (e.g., more than 6 times, such as more than 10 times) wider than it is deep. Typically, in the expanded configuration, upstream support portion **60** has a total height of less than 10 mm (e.g., less than 5 mm, such as less than 2 mm).

Typically, inner perimeter **68** comprises, or is defined by, a free inner edge of upstream support portion **60**. That is, opening **61** resembles a hole cut out of a lamina (e.g., out of a disc). For some applications, inner perimeter **68** com-

## 12

prises, or is defined by, a curved and/or folded inner edge of upstream support portion **60**. If the inner perimeter of upstream support portion **60** comprises, or is defined by, a curved or folded edge, then a radius of curvature of the curved or folded edge is typically less than 2.5 mm, such as less than 1 mm. That is, the curve or fold of the edge is generally sharp, such that when viewed from within opening **61**, the curved or folded edge looks generally like a free edge.

Prosthetic valve support **22** typically comprises two or more tissue-engaging elements **24** (e.g., clips **30**), coupled to inner perimeter **68** of upstream support portion **60**. For such applications, the two tissue-engaging elements are typically disposed opposite each other (e.g., at 180 degrees around inner perimeter **68** from each other).

Typically, tissue-engaging elements **24** (e.g., clips **30**) are coupled to upstream support portion **60** (e.g., inner perimeter **68** thereof) by a flexible connector **70**, which may comprise polyethylene terephthalate (e.g., polyester), polytetrafluoroethylene (e.g., Teflon, ePTFE), a fabric, nitinol, and/or any other suitable material. Thereby, tissue-engaging elements **24** (e.g., clips **30**) are typically flexibly coupled to upstream support portion **60**, and/or are able to move independently of each other. Connector **70** may be coupled to upstream support portion **60** and tissue-engaging elements **24** using sutures, welding, and/or any other suitable technique known in the art.

Prosthetic valve support **22** typically further comprises a stabilizing element **80**, coupled to clips **30** (e.g., to a downstream portion thereof). Typically, stabilizing element **80** forms a ring shape that defines an opening **81** (e.g., an aperture), and is typically inelastic and at least partly flexible. Opening **81** typically, but not necessarily, has a diameter that is generally equal to diameter  $d_4$  of opening **61**.

Non-limiting examples of materials that stabilizing element **80** may comprise include polyethylene terephthalate (e.g., polyester), PTFE (e.g., ePTFE), nylon, cotton, nitinol, stainless steel, nickel cobalt, cobalt chrome, titanium, tantalum and palladium. Typically, and as shown in FIG. 1A, stabilizing element **80** comprises (1) an outer coat **82** of a flexible material (e.g., polyester), which typically provides inelasticity, and (2) an inner strip **84** of a shape-memory material (e.g., nitinol), which is typically configured (e.g., shape-set) to bias element **80** to assume a ring-shaped configuration.

Stabilizing element **80** (and thereby opening **81**) typically has a depth  $d_{11}$  (e.g., a height from a most upstream part to a most downstream part) of less than 20 mm (e.g., less than 10 mm, e.g., less than 5 mm, such as less than 1 mm). As described hereinabove, inner perimeter **68** of upstream support portion has a depth  $d_{10}$  of less than 5 mm. Typically, in the expanded configuration, no part of prosthetic valve support **22** that circumscribes a space that has a perimeter greater than 60 mm (e.g., as upstream support portion **60** and stabilizing element **80** typically do) has a height of more than 20 mm. For some applications, in the expanded configuration, no part of the support that circumscribes a space that has a perimeter greater than 60 mm has a height of more than 10 mm. For some applications, in the expanded configuration, no part of the support that circumscribes a space that has a perimeter greater than 60 mm has a height of more than 5 mm.

Reference is made to FIGS. 2A-D, which are schematic illustrations of prosthetic valve support **22** and/or components thereof, in accordance with respective applications of the invention. As described hereinabove, upstream support portion **60** is generally annular. For some applications, and as shown in FIG. 1A, upstream support portion **60** has a



generally circular outer perimeter **69**. FIG. 2A shows an alternative embodiment in which upstream support portion **60** comprises an upstream support portion **90**, which has a non-circular outer perimeter **99**. FIG. 2A shows outer perimeter **99** as generally oval, with a “squashed” portion **92**. Such a configuration may, for example, facilitate placement of upstream support portion **90** at a mitral valve of the subject, with squashed portion **92** facing the interatrial septum. It is to be noted, that the scope of the invention includes upstream support portions having other shapes, configured according to the anatomical site at which they are to be placed. For example, for some applications, upstream support portion **60** and/or upstream support portion **90** may have radially-protruding bulges or wings (not shown), configured to stabilize the upstream support portion and/or to inhibit leakage between the native valve and the upstream support portion.

As described hereinabove, upstream support portion **60** typically comprises an expandable lattice-structure frame **62**. FIG. 2B shows an alternative embodiment in which upstream support portion **60** comprises a braided upstream support portion **100**, which comprises a braided structure of intertwining strands **102**, at least some of which are slidable past (e.g., over, under) each other. Typically, strands **102** comprise a shape-memory material such as, but not limited to, nitinol. Upstream support portion **100** is transluminally deliverable in a compressed configuration, and is expandable to an annular, expanded configuration at the native valve. Typically, support **100** is configured to automatically expand to the expanded configuration, and this expansion is controlled by progressively releasing (e.g., loosening and/or unthreading) a restricting element **104** (e.g., a drawstring), which, when threaded through parts of upstream support portion **100** (e.g., one or more rings **106** thereof), is configured to restrict expansion of the upstream support portion (e.g., to retain the upstream support portion in the compressed configuration thereof). FIG. 2B shows sequential stages in the deployment of upstream support portion **100** from a delivery tube **108**. Typically, upstream support portion **100** is recompressible by tightening (e.g., pulling) the restricting element.

As described hereinabove, prosthetic valve support **22** comprises one or more tissue-engaging elements **24**, and typically further comprises upstream support portion **60** and/or stabilizing element **80**. FIG. 1A shows prosthetic valve support **22** comprising both upstream support portion **60** and stabilizing element **80**. FIG. 2C shows an alternative embodiment in which prosthetic valve support **22** comprises a prosthetic valve support **322**, which does not comprise stabilizing element **80**. FIG. 2D shows an alternative embodiment in which prosthetic valve support **22** comprises a prosthetic valve support **422**, which does not comprise an upstream support portion (e.g., upstream support portion **60**). For some applications of the invention, when implanted at the native valve, no portion of prosthetic valve support **422** is disposed upstream of the native annulus.

It is to be noted that upstream support portions **90** and **100**, and prosthetic valve supports **322** and **422**, may be used (e.g., combined) with apparatus and methods described elsewhere herein. For example, the upstream support portion of any of the prosthetic valve supports described herein may be replaced with upstream support portion **90** or upstream support portion **100**, resulting in alternative prosthetic valve supports. Furthermore, these resulting prosthetic valve supports, as well as prosthetic valve supports **322** and **422**, may be used in combination with other techniques described

herein (e.g., with reference to FIGS. 3A-I, 4A-F, 5, 6A-B, 7, 8, and/or 9A-C), *mutatis mutandis*.

Reference is made to FIGS. 3A-I, which are schematic illustrations of steps in the delivery and implantation of prosthetic valve support **22** at a native heart valve **120** of heart **250** of a subject, and the use thereof to facilitate implantation of a prosthetic valve **150**, in accordance with some applications of the invention. FIGS. 3A-I show native valve **120** as comprising a mitral valve **122** of the subject, but it is to be noted that the scope of the invention includes the use of prosthetic valve support **22** at other heart valves of the subject.

Mitral valve **122** is disposed between a left atrium **124** and a left ventricle **126** of the subject, and comprises two leaflets **128**. Atrium **124** is upstream of mitral valve **122** and ventricle **126** is downstream of the mitral valve. Prosthetic valve support **22**, in a compressed configuration **30** thereof, is advanced transluminally (e.g., transfemorally and/or transseptally) within a delivery tube **130** of delivery apparatus **140**, to atrium **124**, and between leaflets **128** (FIG. 3A).

Prosthetic valve support **22** is advanced out of delivery tube **130** and/or the delivery tube is withdrawn from the prosthetic valve support (FIG. 3B). Clips **30** (and/or other tissue-engaging elements) are typically disposed at a downstream portion of prosthetic valve support **22** (e.g., downstream of downstream end **71** of upstream support portion **60**) in the compressed configuration thereof, and are thereby exposed from delivery tube **130**. Stabilizing element **80** is also typically exposed from the delivery tube, and typically forms a generally lemniscate (e.g., figure-8) shape, defining two “loops” **83**. Typically, the axis between loops **83** of the lemniscate is generally orthogonal to the axis between clips **30**, and may be used to orient prosthetic valve support **22**, e.g., such that clips **30** point toward leaflets **128** of the native valve. For example, loops **83** may be disposed between chordae tendineae **72** of one leaflet and those of the other leaflet, and physical contact between the chordae tendineae and the loops automatically and/or via tactile feedback to the physician, facilitates orientation of the prosthetic valve support. Alternatively or additionally, the lemniscate shape of stabilizing element **80** may be visualized using imaging techniques such as fluoroscopy and/or ultrasound. Clips **30** are opened (e.g., as described hereinabove with reference to FIG. 1B).

Prosthetic valve support **22** is moved upstream (e.g., proximally) so as to envelope leaflets **128** between clip arms **32** of each clip **30**, and each clip is closed around a leaflet, thereby coupling each clip to a leaflet, e.g., by clamping the leaflet between the clip arms (FIG. 3C). Each clip **30** couples to a single leaflet **128**, such that one clip arm of each clip (e.g., clip arm **32a**) engages an upstream surface of the leaflet (e.g., an upstream side of the leaflet), and the other clip arm of each clip (e.g., clip arm **32b**) engages a downstream surface of the leaflet (e.g., a downstream side of the leaflet). Although each clip typically couples to only one leaflet, for some applications, more than one clip couples to each leaflet.

As described hereinabove, clips **30** (and/or other tissue-engaging elements **24**) are typically coupled to the leaflets of the native valve before prosthetic valve support **22** is fully deployed. Clips **30** are typically locked (e.g., as described with reference to FIG. 1C), and subsequently decoupled from clip controller **36** (e.g., as described with reference to FIG. 1D). FIGS. 3C-F show stages in the deployment of prosthetic valve support **22** (e.g., of upstream support portion **60** thereof). Upstream support portion **60** typically progressively expands as it is exposed from delivery tube



130. Thereby, typically, (1) downstream end 71 of the cylindrical shape of the upstream support portion in the compressed configuration thereof, expands to become inner perimeter 68 of the upstream support portion in the expanded configuration thereof, and (2) subsequently, upstream end 73 of the cylindrical shape expands to become outer perimeter 69 of the upstream support portion.

Delivery apparatus 140 typically comprises a pushing member 132. Typically, prosthetic valve support 22 (e.g., upstream support portion 60 thereof) is reversibly coupled to pushing member 132, and is exposed from delivery tube 130 by being pushed using the pushing member. Upstream support portion 60 is typically configured (e.g., shape-set) to automatically expand toward its expanded configuration upon being deployed from delivery tube 130. For some applications of the invention, the upstream support portion “pops” open from the configuration shown in FIG. 3C to the configuration shown in FIG. 3F, immediately upon exposure of upstream end 73 of the upstream support portion from delivery tube 130.

For some applications, and as shown in FIGS. 3C-F, one or more holding members 134, coupled to, and decouplable from, upstream support portion 60, facilitate controlled expansion of the upstream support portion. For example, holding members 134 may be configured to allow a physician (1) to expand some portions of the upstream support portion before other portions and/or (2) to adjust the positioning of the upstream support portion on the upstream surface of the native valve following expansion of the upstream support portion. For some applications, two holding members 134 are used, and are coupled to opposite sides of upstream support portion 60 to each other (e.g., 180 degrees around the upstream support portion from each other).

For some applications, and as shown in FIGS. 3D-F, three holding members 134 are used. For such applications, each holding member 134 is coupled at between 90 and 180 degrees (e.g., between 100 and 150 degrees, such as at 120 degrees) around the upstream support portion from the other holding members. For some such applications, and as shown in FIG. 3F, the holding members are coupled to the upstream support portion such that, when the upstream support portion is positioned at the native valve, two holding members are disposed generally above respective commissures of the native valve, and the third holding member is disposed generally midway around posterior leaflet 128<sub>p</sub> of the native valve.

For some applications, holding members 134 comprise locking elements and/or coupling leads (e.g., coupling wires, e.g., looped around respective portions of the upstream support portion; not shown in FIGS. 3D-F) that couple the holding members to the upstream support portion, and the holding members are decoupled from the upstream support portion by unlocking the locking elements and/or unlooping the loops. For some applications of the invention, holding members 134 also facilitate retrieval of the upstream support portion, and thereby of prosthetic valve support 22, e.g., as described with reference to FIGS. 4A-F.

FIG. 3G shows prosthetic valve support 22 following coupling, deployment and expansion (i.e., implantation) thereof at mitral valve 122, and withdrawal of delivery apparatus 140. As described hereinabove, prosthetic valve support 22 is configured to be coupled to the native heart valve (e.g., to leaflets thereof) without eliminating check valve functionality of the native heart valve. Typically, and as shown in FIG. 3G, clips 30 couple the prosthetic valve support to leaflets 128 such that (1) the leaflets define a

single orifice, and (2) the native valve functions as a single check valve (e.g., functions in a manner that is generally similar to the natural (e.g., physiological) function of the native valve). Stabilizing element 80 is also configured to allow such movement of leaflets 128, e.g., the stabilizing element is sufficiently flexible to flex in response to the leaflets moving in response to pumping of the heart. FIG. 3G shows (1) in solid, mitral valve 122 (e.g., leaflets 128) closed, and the respective state of prosthetic valve support 22, and (2) in phantom, the mitral valve (e.g., the leaflets) open, and the respective state of the prosthetic valve support.

Thereby, when prosthetic valve support 22 is implanted at an atrioventricular valve of the subject (e.g., mitral valve 122 or a tricuspid valve), clips 30 typically move away from each other during ventricular diastole, and toward each other during ventricular systole. For applications in which prosthetic valve support 22 is implanted at a native semilunar valve of the subject (e.g., an aortic valve or a pulmonary valve), clips 30 typically move toward each other during ventricular diastole, and away from each other during ventricular systole.

Subsequently (e.g., immediately subsequently, or after more than a minute, e.g., after more than 2 minutes, e.g., after more than 5 minutes, such as after more than an hour), a prosthetic valve 150 is transluminally delivered, in a compressed configuration thereof (e.g., within a delivery tube 160), to the native valve, and implanted at the native valve by coupling the prosthetic valve to prosthetic valve support 22. Implantation of prosthetic valve 150 replaces check valve functionality of the native valve with a substitute check valve functionality of the prosthetic valve. The substitute check valve functionality is provided by one or more prosthetic check valve elements (e.g., valve members, such as leaflets, a ball, or a disc), such as those known in the art, which the prosthetic valve comprises (not shown).

Typically, and as shown in FIG. 3H, respective portions of prosthetic valve 150 are placed within opening 61 (defined by upstream support portion 60) and/or opening 81 (defined by stabilizing element 80), and are expanded such that the respective portions engage the upstream support portion and the stabilizing element, respectively. Typically, prosthetic valve 150 is configured to automatically expand upon deployment from delivery tube 160, and radially-expansive force applied by prosthetic valve 150 to upstream support portion 60 and/or stabilizing element 80 facilitates coupling of the prosthetic valve to prosthetic valve support 22.

FIG. 3I shows prosthetic valve 150 having been fully deployed and coupled to prosthetic valve support 22. That is, FIG. 3I shows an implant 180, comprising prosthetic valve support 22 and prosthetic valve 150, having been implanted at native valve 120 (e.g., at mitral valve 122). Prosthetic valve 150 is described in more detail hereinbelow.

Typically, diameter d3 of upstream support portion 60 is greater than a diameter d5 of the native valve (e.g., a diameter of the orifice of the native valve, e.g., an inner diameter of the annulus of the native valve). Further typically, diameter d4 of opening 61 is smaller than diameter d5. When prosthetic valve 150 is expanded within opening 61 of the upstream support portion, a diameter d6 of the prosthetic valve is typically restricted by the upstream support portion to the same diameter as diameter d4 of opening 61. For some applications, contact between prosthetic valve 150 and upstream support portion 60 (e.g., resulting from the radially-expansive force of the valve on the support) couples the prosthetic valve to the prosthetic valve support, and/or inhibits retrograde leakage of blood therebetween.



When implanted at the native valve (e.g., when in respective expanded configurations), a height **d9** of prosthetic valve **150** is typically at least 1.5 times greater (e.g., at least 3 times greater, such as at least 5 times greater) than the total height of upstream support portion **60**. Typically, height **d9** is at least 1.5 times greater (e.g., at least 3 times greater, such as at least 5 times greater) than depth **d10** of opening **61**.

As described hereinabove, upstream support portion **60** is configured to be placed against an upstream side of the native valve. It should be noted, that radial expansion of prosthetic valve **150** against inner perimeter **68** of upstream support portion **60**, thereby typically does not cause the prosthetic valve support to apply a radially-expansive force to the native valve annulus. For some applications of the invention, this expansion of prosthetic valve **150** does not cause the prosthetic valve support to apply the radially-expansive force to the native valve annulus because no part of the prosthetic valve support that circumscribes the prosthetic valve is sandwiched between the prosthetic valve and the native valve annulus.

For some applications, prosthetic valve **150** is couplable to upstream support portion **60** at a plurality of positions along the length of the prosthetic valve. That is, a physician can couple the prosthetic valve at a plurality of depths within the support. For some applications, the prosthetic valve is couplable to the upstream support portion at a continuum of positions along the length of the prosthetic valve. That is, a physician can couple the prosthetic valve to the support at a continuum of depths within the support. For example, in some applications in which the prosthetic valve is configured to be coupled to the upstream support portion solely by the radially-expansive force, the prosthetic valve may be coupled to the upstream support portion at a continuum of positions along the length of the prosthetic valve.

For some applications, sealing between implant **180** and native valve **120** is facilitated by native leaflets **128** being pushed closed against the outer surface of the frame of the valve during systole, in a manner similar to that in which native valve leaflets of a healthy native valve coapt during systole.

For applications in which diameters **d4** and **d6** are relatively large, the proportion (e.g., the surface area) of the native leaflets that is pushed against the outer surface of the valve during systole is relatively large, thereby enhancing the sealing of the native leaflets with respect to the frame of the prosthetic valve. However, for some applications, beyond a given size, as diameters **d4** and **d6** increase, the native valve leaflets are pushed apart at the commissures, thereby potentially increasing a likelihood of paravalvular retrograde leakage of blood at the commissures. Therefore, for some applications of the present invention, prosthetic valve support **22** (and, typically, prosthetic valve **150**) are selected such that diameters **d4** and **d6** are less than 90% (e.g., 5 less than 80%, e.g., less than 60%, such as less than 50%) of diameter **d5** of the native valve (e.g., of the orifice of the native valve). Thus prosthetic valve support **22** facilitates sealing of the prosthetic valve with respect to the native valve, by facilitating closing of the native valve leaflets around the outer surface of the prosthetic valve.

In experiments conducted by the inventors, a prosthetic valve support **22** was implanted in two pigs. Both animals remained alive and stable (e.g., were hemodynamically stable, and had stable breathing rate and oxygen saturation) for a duration of sufficient length to withdraw delivery apparatus **140**, introduce a valve-delivery system, and deploy (e.g., implant) a prosthetic valve in opening **61** of the support. The period between implanting prosthetic valve

support **22** and implanting the prosthetic valve was between 5 and 10 minutes. During this duration, the native valve of the animals functioned generally normally. For example, native leaflet movement and coaptation, and blood flow therebetween was generally normal during this duration.

It is thereby hypothesized that, following implantation of prosthetic valve support **22**, the heart of the subject is able to continue pumping blood sufficiently to support the subject (e.g., to maintain hemodynamic stability) for longer than a minute, e.g., longer than 2 minutes, e.g., longer than 5 minutes, such as longer than an hour. It is thereby hypothesized that a period of generally normal physiological activity of the subject of up to a minute, e.g., up to 2 minutes, e.g., up to 5 minutes, such as up to an hour, between implantation of prosthetic valve support **22** and implantation of a prosthetic valve (e.g., prosthetic valve **150**) is supported by prosthetic valve support **22**. It is thereby hypothesized that, for some applications, the implantation of implant **180** may be performed without the use of cardiopulmonary bypass. It is thereby further hypothesized that replacement of a native valve with implant **180**, may, for some applications, be performed in a human, "off-pump," as was performed in the pig experiments.

Reference is again made to FIG. 3I. For some applications of the invention, the prosthetic valve that is expanded within, and coupled to, prosthetic valve support **22**, comprises a generally cylindrical prosthetic valve. For some applications, the prosthetic valve comprises a prior art prosthetic valve, e.g., a currently commercially-available prosthetic valve. That is, for some applications, prosthetic valve support **22** may be used to facilitate implantation of a prior art prosthetic valve, such as a currently commercially-available prosthetic valve. For some applications, and as shown in FIG. 3I, the prosthetic valve comprises prosthetic valve **150**, which comprises (1) a generally cylindrical valve body **152** (e.g., a primary structural element), within which one or more prosthetic check valve elements (e.g., valve members, such as leaflets, a ball, or a disc) are disposed (not shown), and (2) one or more valve-anchoring elements **154** which protrude (e.g., radially) from the valve body. Typically, valve-anchoring elements **154** are disposed at a downstream end of prosthetic valve **150** (e.g., at a downstream end of valve body **152**), and protrude outward and upstream. For some applications, and as shown in FIG. 3I, valve-anchoring elements **154** fold back toward valve body **152**, and are configured to sandwich stabilizing element **80**, clips **30** and/or native leaflets **128** between the valve-anchoring elements and the valve body. For some applications, prosthetic valve **150** does not comprise valve-anchoring elements **154**.

As described hereinabove, coupling of prosthetic valve **150** to prosthetic valve support **22** is typically facilitated by radially-expansive force applied by the valve to the support. Typically, prosthetic valve **150** comprises an expandable lattice-structure frame **151** (e.g., comprising a plurality of struts). For applications of the invention in which upstream support portion **60** comprises inwardly-protruding barbs **67** (e.g., as shown in FIGS. 1A and 2A), the barbs protrude into frame **151** (e.g., between struts thereof), thereby further facilitating coupling of the prosthetic valve to the prosthetic valve support.

Typically, at least portions of the inner surface of prosthetic valve **150** (e.g., of valve body **152**) are covered with a covering **156**, to facilitate channeling of blood through the valve body, as is known in the art. That is, at least portions of prosthetic valve **150** (e.g., of valve body **152**) are lined with covering **156**. Covering **156** may comprise the same



material(s) as covering **64** described hereinabove, and/or may comprise other materials.

For some applications, an upstream portion of prosthetic valve **150** (e.g., of valve body **152**) alternatively or additionally comprises a netting **158**, which facilitates coupling of the prosthetic valve to prosthetic valve support **22**. Netting **158** may be disposed on the inner surface and/or the outer surface of the upstream portion of the prosthetic valve (e.g., of valve body **152**), and/or between the struts of frame **151**. Typically, netting **158** is disposed upstream of a point at which leaflets **182** contact (e.g., seal around) valve body **152**.

Typically, netting **158** facilitates coupling of prosthetic valve **150** to prosthetic valve support **22** by providing a higher-resolution lattice through which barbs **67** of the prosthetic valve support are configured to protrude. Netting **158** may additionally insulate respective metallic surfaces of the prosthetic valve and the prosthetic valve support (e.g., of frames **62** and **151**) from each other. It is hypothesized that this insulation reduces fatigue, corrosion, chipping and/or wear of the metallic surfaces, and/or electrostatic discharge between the metallic surfaces.

For some applications, a material that inhibits (e.g., prevents) tissue growth (e.g., polytetrafluoroethylene (PTFE), and/or pericardium) may be disposed on a surface of prosthetic valve **150** and/or prosthetic valve support **22** (e.g., clips **30** thereof). Alternatively or additionally, a material that facilitates (e.g., enhances) tissue growth (such as polyethylene terephthalate; PET) may be disposed on a surface of the prosthetic valve and/or the prosthetic valve support (e.g., clips **30** thereof), in order to facilitate sealing and/or coupling to the native valve.

It is hypothesized that the use of prosthetic valve support **22** advantageously facilitates delivery of a prosthetic valve via a catheter narrower than 28 Fr (i.e., less than 9.3 mm), e.g., narrower than 24 Fr (i.e., less than 8 mm), such as by allowing the use of a “minimalistic” prosthetic valve, comprising a generally cylindrical valve body, and valve members (e.g., leaflets) disposed therein, and comprising few or no other components and/or appendages. Typically, prosthetic valve support **22** is also delivered via a similarly narrow catheter, e.g., via the same catheter. The use of such a narrow catheter advantageously facilitates transluminal (e.g., transfemoral) delivery and implantation of the prosthetic valve and prosthetic valve support.

It is to be noted that, although FIGS. **3A-I** show prosthetic valve support **22** being implanted and used to facilitate implantation of a prosthetic valve, the techniques described may be applied to other prosthetic valve supports described herein (e.g., prosthetic valve supports **220**, **322**, **422** and **522**), *mutatis mutandis*.

Reference is made to FIGS. **4A-F**, which are schematic illustrations of a system **200** for facilitating controlled expansion and/or retrievability of upstream support portion **60**, in accordance with some applications of the invention. System **200** comprises one or more holding members **134**, reversibly coupled to upstream support portion **60** by one or more coupling leads **202** (e.g., coupling wires). Typically, two or more (e.g., three) holding members are coupled to the upstream support portion via two or more (e.g., three) coupling leads. Typically, the ends of each coupling lead **202** are disposed within holding members **134**, or more proximally (e.g., outside a body of the subject). Coupling leads **202** may comprise metallic wire, suture, or any other suitable material.

A portion (e.g., a middle portion) of each coupling lead **202** is disposed within (e.g., threaded and/or looped

through) a respective portion of upstream support portion **60**, thereby coupling the upstream support portion to holding members **134**. Typically, this middle portion of each coupling lead is disposed through a peripheral region (e.g., close to an outer edge **69**) of the prosthetic valve support.

For example, and as shown in FIG. **4A**, three coupling leads **202** (e.g., coupling leads **202a**, **202b**, and **202c**) couple three respective holding members **134** (e.g., holding members **134a**, **134b** and **134c**) to upstream support portion **60**. One end of each coupling lead **202** extends from a respective holding member **134**, passes around (e.g., is looped and/or threaded through) upstream support portion **60**, and returns to the same holding member. Thereby, each coupling lead is configured to apply a respective annular pulling force to the entire upstream support portion, when the coupling lead is pulled.

For some applications of the invention, system **200** is configured to facilitate transluminal retrieval of upstream support portion **60** following expansion of the upstream support portion at the native valve. Upstream support portion **60** is deployed at the native valve, e.g., as described with reference to FIGS. **3C-F**, *mutatis mutandis*. Should it be desirable and/or necessary to retrieve upstream support portion **60** into delivery tube **130**, and/or to remove the upstream support portion entirely from the subject, pulling of coupling leads **202** recompresses upstream support portion **60** into a generally cylindrical configuration, e.g., toward and/or into the compressed delivery configuration thereof (FIGS. **4B-D**). Subsequently, upstream support portion **60** may be withdrawn into delivery tube **130** (FIGS. **4E-F**).

System **200** may alternatively or additionally be configured to facilitate controlled expansion of upstream support portion **60**. During deployment of upstream support portion **60**, coupling leads **202** are gradually released (e.g., fed distally). This technique may be understood by considering FIGS. **4B-F** in reverse order, *mutatis mutandis*. Thereby, the rate of expansion of upstream support portion **60** is controllable. Alternative configurations and/or arrangements of coupling leads **202** may be used, e.g., to facilitate controlled expansion of different portions of upstream support portion **60**.

It is to be noted that the techniques described with reference to FIGS. **4A-F** may be used in combination with other upstream support portions described herein (e.g., upstream support portions **90** and **100**), *mutatis mutandis*.

Reference is made to FIG. **5**, which is a schematic illustration of a step in the implantation of prosthetic valve support **22**, in accordance with some applications (e.g., alternative applications) of the invention. For some applications, the step shown in FIG. **5** is performed after the implantation sequence steps shown in FIGS. **3A-3D**, and prior to the steps shown in FIGS. **3F-3I**, e.g., instead of or in addition to the step shown in FIG. **3E**, *mutatis mutandis*. FIG. **5** shows prosthetic valve support subsequent to the coupling of clips **30** to leaflets **128** of the native valve, and prior to the complete release (e.g., the complete expansion) of upstream support portion **60**.

For some applications of the invention, it may be desirable and/or necessary to hold clips **30** closer together than they would otherwise be disposed following complete release, and thereby expansion, of upstream support portion **60**. FIG. **5** shows clips **30** being held closer together, by holding of portions of upstream support portion **60** that are in the vicinity of clips **30**, closer together. At least one coupling lead (e.g., coupling wire) **210** is coupled to these portions of upstream support portion **60**, and holds the



## 21

portions together, as shown in FIG. 5. Coupling lead 210 may comprise metallic wire, suture, or any other suitable material.

At a later time (e.g., closer to a time at which prosthetic valve 150 is to be implanted, such as at the time at which the prosthetic valve is implanted), coupling lead 210 is released, such that the upstream support portion (and the prosthetic valve support as a whole) moves toward the configuration shown in FIGS. 3F and/or 3G.

For example, and as shown in FIG. 5, two or more coupling leads 210 may extend through a holding member 212, and loop through respective portions of upstream support portion 60. The coupling leads are decoupled from the skirt by releasing one end of each coupling lead, and unlooping the coupling lead from the upstream support portion. For some applications, holding member 212 comprises holding member 134, e.g., as described with reference to FIGS. 3C-F.

It is to be noted that the techniques described with reference to FIG. 5 may be combined with other techniques and apparatus described herein. For example, the techniques described with reference to FIG. 5 may be used for implanting other prosthetic valve supports described herein, mutatis mutandis.

Reference is made to FIGS. 6A-B, which are schematic illustrations of a prosthetic valve support 522, comprising tissue-engaging elements 24 that are couplable to each other, and decouplable from each other (e.g., reversibly coupled to each other), in accordance with some applications of the invention. Prosthetic valve support 522 typically further comprises upstream support portion 60 and/or stabilizing element 80, and the tissue-engaging elements of the prosthetic valve support typically comprise clips 30. For some applications, prosthetic valve support 522 comprises prosthetic valve support 22 (e.g., as described with reference to FIGS. 1A-D), and/or may be used in combination with techniques described herein (e.g., with reference to FIGS. 3A-I and/or 8), mutatis mutandis. For some applications, prosthetic valve support 522 does not comprise stabilizing element 80 (e.g., as described for prosthetic valve support 322 with reference to FIG. 2C, mutatis mutandis), and/or does not comprise upstream support portion 60 (e.g., as described for prosthetic valve support 422 with reference to FIG. 2D, mutatis mutandis). Similarly, the tissue-engaging elements of other prosthetic valve supports described herein may be reversibly coupled to each other as described for the tissue-engaging elements of prosthetic valve support 522, mutatis mutandis. Typically, prosthetic valve support 522 is provided with tissue-engaging elements 24 fixedly coupled to each other, and configured to be transluminally, intracorporeally decoupled from each other. Alternatively or additionally, tissue-engaging elements 24 may be configured to be extracorporeally and/or intracorporeally (e.g., transluminally) couplable to each other by a physician.

FIGS. 6A-B show prosthetic valve support 522 following implantation thereof at the native valve (e.g., as shown in FIGS. 3A-F, mutatis mutandis), and before coupling of a prosthetic valve to the prosthetic valve support (e.g., as shown in FIGS. 3H-I, mutatis mutandis), e.g., instead of or in addition to the step shown in FIG. 3G, mutatis mutandis. For some applications, FIG. 6A is thereby comparable to FIG. 3G, mutatis mutandis.

FIG. 6B shows a view from upstream of mitral valve 122 (e.g., from left atrium 124), showing the valve (e.g., leaflets 128) moving (e.g., beating) between open and closed states thereof. As is known in the art, each leaflet 128 of mitral valve 122 is generally defined as being divided into three

## 22

scallops: scallops A1, A2 and A3 of the anterior leaflet, and scallops P1, P2 and P3 of the posterior leaflet. Tissue-engaging elements 24 are coupled to respective portions of leaflets 128 (e.g., scallops A2 and P2 of the anterior and posterior leaflets, respectively), and to each other, and thereby hold the portions of the leaflets to which they are coupled, close to each other (e.g., together). Portions of the leaflets that are not held close to each other (e.g., at least portions of scallops P1, P3, A1 and A3) are typically generally able to move (e.g., flap) in response to beating of the heart. Thereby, the implantation of prosthetic valve support 522 shown in FIGS. 6A-B generates two orifices 530, each orifice defined by (e.g., surrounded by) a respective portion of each leaflet, and thereby, in effect, functioning as a respective check valve. For example, the native valve may function as two (e.g., parallel) check valves. For some applications of the invention, the resulting arrangement of leaflets 128 resembles the “double-orifice” arrangement of leaflets of a valve that has been repaired using the Alfieri stitch, as is known in the mitral valve repair art. Thereby, prosthetic valve support 522 is configured to be coupled to the native heart valve (e.g., to leaflets thereof) without eliminating check valve functionality of the native heart valve, by coupling together respective portions of the two leaflets, such that (1) the native leaflets define two orifices, and (2) the native valve functions as two (e.g., parallel) check valves (e.g., in a manner that is modified with respect to the natural function of the native valve).

Subsequently (e.g., immediately subsequently, or after more than a minute, e.g., after more than 2 minutes, e.g., after more than 5 minutes, such as after more than an hour), a prosthetic valve is transluminally delivered, and implanted at the native valve by coupling the prosthetic valve to prosthetic valve support 522 (e.g., as described with reference to FIGS. 3H-I, mutatis mutandis). Prior to (e.g., immediately prior to) implantation of the prosthetic valve, tissue-engaging elements 24 are decoupled from each other, such that the tissue-engaging elements (and thereby leaflets 128) are movable away from each other, and such that the prosthetic valve may be disposed therebetween during coupling of the prosthetic valve to the prosthetic valve support. For some applications of the invention, between (1) the decoupling of the tissue-engaging elements from each other, and (2) the coupling of the prosthetic valve to the prosthetic valve support, the prosthetic valve support allows (1) the native valve (e.g., the leaflets thereof) to define a single orifice, and (2) the native valve to function as a single check valve (e.g., as described with reference to FIG. 3G, mutatis mutandis).

For some applications of the invention, tissue-engaging elements 24 are coupled to each other by a locking element (e.g., a locking wire), and the locking element is unlocked (e.g., the locking wire is cut or otherwise decoupled), prior to implantation of the prosthetic valve support. For some applications of the invention, tissue-engaging elements 24 are coupled to each other by a coupling lead that which is held in place, and removed, decoupled, and/or loosened immediately prior to implantation of the prosthetic valve. For example, the coupling lead may extend through a holding member and be looped through and/or around the tissue-engaging elements. For some such applications, the holding member may comprise holding member 212, and the coupling lead may comprise coupling lead 210 (e.g., described with reference to FIG. 5, mutatis mutandis), the coupling lead being coupled to tissue-engaging elements 24, rather than to portions of the upstream support portion. For some applications of the invention, prosthetic valve support



**522** is configured such that the tissue-engaging elements are decoupled (e.g., automatically) when the prosthetic valve is implanted at the native valve (e.g., when the prosthetic valve is expanded within the prosthetic valve support).

It is hypothesized that, following implantation of prosthetic valve support **522**, the heart of the subject is able to continue pumping blood sufficiently to support the subject and/or to maintain hemodynamic stability for longer than a minute, e.g., longer than 2 minutes, e.g., longer than 5 minutes, such as longer than an hour. It is thereby hypothesized that a period of generally normal physiological activity of the subject of up to a minute (e.g., up to 2 minutes, e.g., up to 5 minutes, such as up to an hour) between implantation of prosthetic valve support **522** and implantation of a prosthetic valve, is supported by prosthetic valve support **522**. It is thereby hypothesized that the implantation of an implant comprising prosthetic valve support **522** and a prosthetic valve, may be performed without the use of cardiopulmonary bypass. It is thereby hypothesized that replacement of a native valve with such an implant may be performed in a human, "off-pump."

It is to be noted that the techniques described with reference to FIGS. **6A-B** may be combined with other techniques and apparatus described herein. For example, tissue-engaging elements (e.g., clips) of other prosthetic valve supports described herein may be reversibly coupled to each other, so as to achieve the double-orifice configuration of the native valve described with reference to FIGS. **6A-B**, *mutatis mutandis*.

Reference is made to FIG. **7**, which is a schematic illustration of a prosthetic valve support **220**, comprising upstream support portion **60** and three clips **30** (or other tissue-engaging elements **24**), in accordance with some applications of the invention. Clips **30** are typically coupled to upstream support portion **60** via connectors **70**, as described hereinabove, *mutatis mutandis*. For some applications, and as shown in FIG. **7**, prosthetic valve support **220** is configured to be coupled to mitral valve **122** of the subject. One clip **30** is configured to be coupled to anterior leaflet **128a** of the mitral valve (e.g., to the **A2** scallop thereof), and two clips are configured to be coupled to posterior leaflet **128b** (e.g., to the **P1** and **P3** scallops thereof, respectively). For some applications, prosthetic valve support **220** is configured to be coupled to a native tricuspid valve of the subject, and each clip **30** is configured to be coupled to a respective leaflet of the tricuspid valve.

It is to be noted that the techniques described with reference to FIG. **7** may be combined with other techniques and apparatus described herein. For example, other prosthetic valve supports described herein (e.g., prosthetic valve supports **220**, **322**, **422** and **522**) may comprise three tissue-engaging elements, *mutatis mutandis*.

Reference is made to FIG. **8**, which is a schematic illustration of implantation, in heart **250** of the subject, of a prosthetic valve **240**, facilitated by prosthetic valve support **22**, in accordance with some applications of the invention. For some applications, prosthetic valve **240** comprises and/or has features of prosthetic valve **150**, described hereinabove. For some applications, and as shown in FIG. **3H**, both the prosthetic valve support and the prosthetic valve are configured to be delivered from the upstream side of mitral valve **122**, e.g., transfemorally and/or transseptally. For some applications of the invention, the prosthetic valve is configured to be delivered via a retrograde approach. For example, and as shown in FIG. **8**, following implantation of prosthetic valve support **22** at mitral valve **122**, prosthetic valve **240** is delivered via left ventricle **126**, e.g., via aorta

**252** such as via the femoral artery of the subject. Alternatively, prosthetic valve **240** may be delivered transapically. For applications in which the prosthetic valve is delivered via a retrograde approach, prosthetic valve support **22** is typically delivered as described hereinabove, but may alternatively be delivered via a retrograde approach.

It is to be noted that the techniques described with reference to FIG. **8** may be combined with other techniques and apparatus described herein. For example, the techniques described with reference to FIG. **8** may be used for implanting other prosthetic valves described herein, and/or for delivering a prosthetic valve to other prosthetic valve supports described herein, *mutatis mutandis*.

Reference is made to FIGS. **9A-C**, which are schematic illustrations of prosthetic valve supports, each comprising upstream support portion **60**, coupled to tissue-engaging elements **24** (comprising clips **30**) via one or more variable-length connectors **260**, in accordance with respective applications of the invention. Variable-length connectors **260** are typically positioned in the same or similar way as connectors **70**, and typically perform the same or similar functions as connectors **70**, described hereinabove.

FIG. **9A** shows a prosthetic valve support **270**, comprising variable-length connectors **260**, embodied as adjustable-length connectors **272**, in accordance with some applications of the invention. Connectors **272** comprise a holding wire **274**, which is slidably coupled to upstream support portion **60**, is fixedly coupled to tissue-engaging elements **24**, and defines a rack **276**, comprising a plurality of teeth **277**, disposed along at least part of the length of the holding wire. The distance between upstream support portion **60** (e.g., inner perimeter **68** thereof) and each tissue-engaging element **24** is adjustable by adjusting the length of the respective holding wire **274** that is disposed between the upstream support portion and the tissue-engaging element. Typically, this length is adjusted by pulling the holding wire proximally. Thereby, the length of connectors **272** is variable, by the connectors being adjustable.

An engaging element **278** (e.g., a pawl, a ridge, or a tooth), typically within a ratchet housing **280**, allows the length of holding wire **274** between the upstream support portion and the clip to be shortened, but not to be lengthened. Thereby, holding wire **274** (e.g., rack **276** thereof) and ratchet housing **280** (e.g., engaging element **278** thereof) act as a ratchet. For some applications, and as shown in FIG. **9A**, ratchet housing **280** is movable with respect to upstream support portion **60**, and is slid distally over holding wire **274**, such as by a pusher **282** (e.g., a controller tube). Alternatively, ratchet housing **280** is fixedly coupled to upstream support portion **60**, e.g., such that the length of holding wire **274** is adjusted by pulling the holding wire proximally. Typically, but not necessarily, the length of holding wire **274** (and thereby of connectors **272**) is adjusted subsequent to coupling of clips **30** to the native leaflets, and further typically, also subsequent to deployment of upstream support portion **60**.

FIG. **9B** shows a prosthetic valve support **290**, comprising variable-length connectors **260**, embodied as elastic connectors **292** (e.g., stretchable connectors), in accordance with some applications of the invention. Connectors **292** comprise one or more (e.g., two) elastic elements **294**, such as tension springs (e.g., coil tension springs). The distance between upstream support portion **60** (e.g., inner perimeter **68** thereof) and each clip is variable due to stretching and contracting of elastic elements **294**. Thereby, the length of connectors **292** is variable, by the connectors being elastic.



The length, elasticity and/or force constant of elastic elements **294** may be adapted to the native valve to which prosthetic valve support **290** is coupled, and/or to the individual subject (e.g., pre-selected according to the native valve and/or the individual subject). For example, elastic elements that have a relatively low force constant may allow leaflets of the native valve to move more freely, and elastic elements that have a relatively high force constant may couple the prosthetic valve support to the native valve more fixedly. Alternatively or additionally, connectors **260** may be configured to stretch and contract with movement (e.g., flapping) of the leaflets of the native valve, may thereby allow the leaflets to move more freely compared to some inelastic connectors, and may thereby facilitate the coupling of the prosthetic valve support to the native valve without eliminating check valve functionality of the native valve.

FIG. **9C** shows a prosthetic valve support **300**, comprising variable-length connectors **260**, embodied as elastic connectors **302**, in accordance with some applications of the invention. Connectors **302** comprise an elastic element **304**, such as a tension spring (e.g., a coil tension spring). For some applications, elastic element **304** comprises elastic element **294**, described with reference to FIG. **9B**. Connectors **302** further comprise a restrictor **306**, which restricts elasticity of element **304**. Typically, restrictor **306** holds elastic element **304** in an expanded (e.g., stretched) state. Typically, restrictor **306** is releasable (e.g., decouplable) from elastic element **304**, so as to allow the elastic element to contract.

For some applications, restrictor **306** may be mechanically releasable (e.g., removable) by the user. For some applications, and as shown in FIG. **9C**, restrictor **306** may comprise a material that disintegrates in the body (e.g., a material that is at least in part soluble and/or biodegradable and/or biosorbent). For such applications, restrictor **306** typically disintegrates over a predictable period of time e.g., between 15 minutes and 1 week, such as between 30 minutes and 3 days, for example, between 1 hour and 1 day. For some applications, restrictor **306** is configured to decouple from (i.e., release) elastic element **304** gradually, e.g., in stages. For some applications, restrictor **306** is coupled to elastic element **304** and/or another part of prosthetic valve support **300**, such that, following the release of the elastic element, the restrictor is retained, so as not to enter the vasculature of the subject.

For some applications of the invention, prosthetic valve support **300** and connectors **302** are used in instances in which it is desirable to have a first period during which the connectors are longer (e.g., prior to implantation of a prosthetic valve), and a second period during which the connectors are shorter (e.g., subsequent to implantation of the prosthetic valve).

Reference is again made to FIGS. **9A-C**. It should be noted that throughout this patent application, including in the claims, the term “variable”, with respect to the length of the connectors that couple tissue-engaging elements **24** (e.g., clips **30**) to upstream support portion **60**, includes (1) length variability due to intervention, such as a physician adjusting the length (e.g., as described for adjustable-length connectors **272**), and (2) length variability due to elasticity and/or another configuration that facilitates the connector changing length, such as without intervention (e.g., as described for elastic connectors **292** and **302**). It is hypothesized that, for some applications, connector length variability (1) facilitates reduction of valve regurgitation prior to implantation of the prosthetic valve (2) provides adjustability for anatomical differences (e.g., leaflet size) between subjects, and/or (3)

increases stability of the prosthetic valve, e.g., by reducing axial rotation of the prosthetic valve, such as by the connector length being shortened after implantation of the prosthetic valve.

It is to be noted that the apparatus and techniques described with reference to FIGS. **9A-C** may be combined with other techniques and apparatus described herein. For example, any of the prosthetic valve supports may comprise variable-length connectors **260** (e.g., adjustable-length connectors **272**, elastic connectors **292**, and/or elastic connectors **302**), mutatis mutandis. Similarly, connector length adjustment may be used in combination with the implantation techniques described with reference to FIGS. **3A-I** and/or **8**, mutatis mutandis.

Reference is again made to FIGS. **1A-9C**. For some applications of the invention, one or more of the elements, portions and/or components described hereinabove comprise radiopaque markers so as to facilitate implantation thereof (e.g., by using imaging techniques such as fluoroscopy). For example, tissue-engaging elements **24** (e.g., clips **30**) and/or stabilizing element **80** may comprise radiopaque markers, e.g., so as to facilitate positioning (e.g., orientation) of the prosthetic valve support with respect to the native valve. Alternatively or additionally, inner perimeter **68** of upstream support portion **60** and/or stabilizing element **80** may comprise radiopaque markers, e.g., so as to indicate the opening(s) in which the prosthetic valve is to be implanted. Alternatively or additionally, the prosthetic valve may comprise radiopaque markers to facilitate positioning thereof with respect to the prosthetic valve support.

Reference is again made to FIGS. **1A-9C**. For some applications of the invention, the tissue-engaging elements of the prosthetic valve supports described hereinabove are movable with respect to each other at at least some time subsequent to the coupling of the tissue-engaging elements being coupled to the leaflets of the native valve. For example, tissue-engaging elements **24** (e.g., clips **30**) of prosthetic valve support **22** are movable with respect to each other, e.g., as shown in FIG. **3G**. Similarly, tissue-engaging elements **24** (e.g., clips **30**) of prosthetic valve support **522** are movable with respect to each other once they have been decoupled from each other.

Reference is again made to FIGS. **1A-9C**. The prosthetic valve supports described hereinabove are typically configured to be coupled to the leaflets of the native valve without eliminating check-valve functionality of the native valve. That is, although the coupling of the prosthetic valve support to the native valve may alter the position and/or movement of the native leaflets, the native valve still facilitates at least some net one-way movement of blood therethrough (e.g., as described with reference to FIGS. **3G** and **6A-B**). For some such instances, the altered position and/or movement of the native leaflets may, in fact, enhance check valve functionality of the native valve, thereby substantially “repairing” the native valve. For some such instances, a physician may choose not to implant a prosthetic valve during the same procedure as the implantation of the prosthetic valve support, but instead may choose to allow the subject to return to activities of daily living, whilst retaining the option to implant a prosthetic valve at a later date. That is, for some applications of the invention, the prosthetic valve support is configured to be implanted without a prosthetic valve, and to provide (1) repair of the native valve, and (2) an implantation site that is pre-prepared for subsequent implantation of a prosthetic valve at a later date, should such implantation be subsequently considered necessary.



It is to be noted that, although some techniques described hereinabove are generally illustrated as being used at the mitral valve of the subject, the scope of the invention includes implanting a prosthetic valve support and prosthetic valve (e.g., those described hereinabove) at other native heart valves of the subject, such as at the tricuspid valve, the aortic valve, or the pulmonary valve of the subject, *mutatis mutandis*.

It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.

The invention claimed is:

1. A heart valve repair system, comprising:

a delivery sheath having a proximal end and a distal end; and

an implant configured to be coupled to first and second native leaflets of a native heart valve of a patient, the implant comprising:

a frame (1) comprising a braided structure of intertwining strands and (2) having a surface configured to contact an upstream surface of the native heart valve; and

first and second gripping members coupled to the frame, each of the first and second gripping members including (i) a ventricular arm, the ventricular arm having first and second ends, and (ii) an atrial arm, wherein for each of the gripping members:

(A) the ventricular arm is movable toward a central longitudinal axis of the implant, and

(B) due to the moving of the ventricular arm toward the central longitudinal axis, the second end of the ventricular arm moves toward the central longitudinal axis more than the first end of the ventricular arm moves toward the central longitudinal axis of the implant,

wherein the implant is disposed in the delivery sheath in a delivery state in which:

the frame has a proximal end, closer to the proximal end of the delivery sheath, and a distal end, closer to the distal end of the delivery sheath,

the frame is shaped to define a wall fully surrounding, from a proximal end of the wall to a distal end of the wall, the central longitudinal axis of the implant, the proximal end of the wall defining a proximal opening of the frame, and the distal end of the wall defining a distal opening of the frame, and

the distal end of the wall is disposed proximally to the second end of the ventricular arm of each of the gripping members.

2. The heart valve repair system of claim 1, wherein the frame comprises a lattice structure frame.

3. The heart valve repair system of claim 1, wherein the frame comprises a plurality of struts.

4. The heart valve repair system of claim 1, wherein:

the implant is disposed in the delivery sheath in an extended state, and

the implant is configured to assume an implanted state in which, following the moving of the ventricular arm of each of the gripping members toward the central longitudinal axis of the implant, a longitudinal length of

the implant in the implanted state is shorter than a longitudinal length of the implant while in the extended state.

5. The heart valve repair system of claim 1, wherein the implant is configured to assume an implanted state following the moving of the ventricular arm of each of the gripping members toward the central longitudinal axis of the implant, and wherein, in the implanted state, the first and second gripping members are configured to allow the first and second native leaflets to function as a check-valve.

6. The heart valve repair system according to claim 1, wherein the implant does not comprise a prosthetic heart valve.

7. The heart valve repair system of claim 1, wherein for each of the gripping members, one of the arms of the gripping member has a free end, and wherein the implant is disposed within the delivery sheath in a manner in which a flexible portion of the implant is disposed proximal to the free ends of the gripping members.

8. The heart valve repair system of claim 7, wherein the flexible portion comprises nitinol and fabric.

9. A heart valve repair system, comprising:

a delivery sheath having a proximal end and a distal end; and

an implant configured to be coupled to first and second native leaflets of a native heart valve of a patient, the implant comprising:

a frame having a surface configured to contact an upstream surface of the native heart valve; and

first and second gripping members coupled to the frame, each of the first and second gripping members including (i) a ventricular arm, the ventricular arm having first and second ends, and (ii) an atrial arm, wherein for each of the gripping members:

(A) the ventricular arm is movable toward a central longitudinal axis of the implant, and

(B) due to the moving of the ventricular arm toward the central longitudinal axis, the second end of the ventricular arm moves toward the central longitudinal axis more than the first end of the ventricular arm moves toward the central longitudinal axis of the implant,

wherein the implant is disposed in the delivery sheath in a delivery state in which:

the frame has a proximal end, closer to the proximal end of the delivery sheath, and a distal end, closer to the distal end of the delivery sheath,

the frame is shaped to define a wall fully surrounding, from a proximal end of the wall to a distal end of the wall, the central longitudinal axis of the implant, the proximal end of the wall defining a proximal opening of the frame, and the distal end of the wall defining a distal opening of the frame, and

the distal end of the wall is disposed proximally to the second end of the ventricular arm of each of the gripping members, and

wherein the implant is configured to assume an implanted state in which, following the moving of the ventricular arm of each of the gripping members toward the central longitudinal axis of the implant, the first and second gripping members form the first and second native leaflets into a double orifice, each orifice configured to function as a respective check-valve.

10. The heart valve repair system of claim 9, wherein:

the implant is disposed in the delivery sheath in an extended state, and



29

the implant is configured to assume an implanted state in which, following the moving of the ventricular arm of each of the gripping members toward the central longitudinal axis of the implant, a longitudinal length of the implant in the implanted state is shorter than a longitudinal length of the implant while in the extended state.

11. The heart valve repair system of claim 9, wherein the implant is configured to assume an implanted state following the moving of the ventricular arm of each of the gripping members toward the central longitudinal axis of the implant, and wherein, in the implanted state, the first and second gripping members are configured to allow the first and second native leaflets to function as a check-valve.

12. The heart valve repair system according to claim 9, wherein the implant does not comprise a prosthetic heart valve.

13. The heart valve repair system of claim 9, wherein for each of the gripping members, one of the arms of the gripping member has a free end, and wherein the implant is disposed within the delivery sheath in a manner in which a flexible portion of the implant is disposed proximal to the free ends of the gripping members.

14. The heart valve repair system of claim 13, wherein the flexible portion comprises nitinol and fabric.

15. A heart valve repair system, comprising:  
a delivery sheath having a proximal end and a distal end;  
and

an implant configured to be coupled to first and second native leaflets of a native heart valve of a patient, the implant comprising:

a frame having a surface configured to contact an upstream surface of the native heart valve; and

first and second gripping members coupled to the frame, each of the first and second gripping members including (i) a ventricular arm, the ventricular arm having first and second ends, and (ii) an atrial arm, wherein for each of the gripping members:

(A) the ventricular arm is movable toward a central longitudinal axis of the implant, and

(B) due to the moving of the ventricular arm toward the central longitudinal axis, the second end of the ventricular arm moves toward the central longitudinal axis more than the first end of the ventricular arm moves toward the central longitudinal axis of the implant,

wherein the implant is disposed in the delivery sheath in a delivery state in which:

the frame has a proximal end, closer to the proximal end of the delivery sheath, and a distal end, closer to the distal end of the delivery sheath,

the frame is shaped to define a wall fully surrounding, from a proximal end of the wall to a distal end of the wall, the central longitudinal axis of the implant, the proximal end of the wall defining a proximal opening of the frame, and the distal end of the wall defining a distal opening of the frame, and

the distal end of the wall is disposed proximally to the second end of the ventricular arm of each of the gripping members, and

wherein the heart valve repair system further comprises an elongate control member that is:

movable within the delivery sheath,  
reversibly couplable to the implant, and  
extracorporeally controllable to facilitate the moving of each of the ventricular arms,

30

wherein in the delivery state, the wall of the frame surrounds a space through which the elongate control member is movable.

16. The heart valve repair system of claim 15, wherein the elongate control member is decouplable from the implant and withdrawable through the frame following the moving of the ventricular arm of each of the gripping members toward the central longitudinal axis of the implant.

17. The heart valve repair system of claim 15, wherein: the implant is disposed in the delivery sheath in an extended state, and

the implant is configured to assume an implanted state in which, following the moving of the ventricular arm of each of the gripping members toward the central longitudinal axis of the implant, a longitudinal length of the implant in the implanted state is shorter than a longitudinal length of the implant while in the extended state.

18. The heart valve repair system of claim 15, wherein the implant is configured to assume an implanted state following the moving of the ventricular arm of each of the gripping members toward the central longitudinal axis of the implant, and wherein, in the implanted state, the first and second gripping members are configured to allow the first and second native leaflets to function as a check-valve.

19. The heart valve repair system according to claim 15, wherein the implant does not comprise a prosthetic heart valve.

20. The heart valve repair system of claim 15, wherein for each of the gripping members, one of the arms of the gripping member has a free end, and wherein the implant is disposed within the delivery sheath in a manner in which a flexible portion of the implant is disposed proximal to the free ends of the gripping members.

21. The heart valve repair system of claim 20, wherein the flexible portion comprises nitinol and fabric.

22. A heart valve repair system, comprising:  
a delivery sheath having a proximal end and a distal end;  
and

an implant configured to be coupled to first and second native leaflets of a native heart valve of a patient, the implant comprising:

a frame having a surface configured to contact an upstream surface of the native heart valve; and

first and second gripping members coupled to the frame, each of the first and second gripping members including (i) a ventricular arm, the ventricular arm having first and second ends, and (ii) an atrial arm, wherein for each of the gripping members:

(A) the ventricular arm is movable toward a central longitudinal axis of the implant, and

(B) due to the moving of the ventricular arm toward the central longitudinal axis, the second end of the ventricular arm moves toward the central longitudinal axis more than the first end of the ventricular arm moves toward the central longitudinal axis of the implant,

wherein the implant is disposed in the delivery sheath in a delivery state in which:

the frame has a proximal end, closer to the proximal end of the delivery sheath, and a distal end, closer to the distal end of the delivery sheath,

the frame is shaped to define a wall fully surrounding, from a proximal end of the wall to a distal end of the wall, the central longitudinal axis of the implant, the proximal end of the wall defining a proximal opening



**31**

of the frame, and the distal end of the wall defining a distal opening of the frame, and  
 the distal end of the wall is disposed proximally to the second end of the ventricular arm of each of the gripping members, and

wherein the implant further comprises first and second gripping member mounts to which the first and second gripping members are mounted, respectively.

**23.** The heart valve repair system according to claim **22**, wherein each of the gripping member mounts is shaped as a strip.

**24.** The heart valve repair system of claim **22**, wherein: the implant is disposed in the delivery sheath in an extended state, and

the implant is configured to assume an implanted state in which, following the moving of the ventricular arm of each of the gripping members toward the central longitudinal axis of the implant, a longitudinal length of the implant in the implanted state is shorter than a longitudinal length of the implant while in the extended state.

**32**

**25.** The heart valve repair system of claim **22**, wherein the implant is configured to assume an implanted state following the moving of the ventricular arm of each of the gripping members toward the central longitudinal axis of the implant, and wherein, in the implanted state, the first and second gripping members are configured to allow the first and second native leaflets to function as a check-valve.

**26.** The heart valve repair system according to claim **22**, wherein the implant does not comprise a prosthetic heart valve.

**27.** The heart valve repair system of claim **22**, wherein for each of the gripping members, one of the arms of the gripping member has a free end, and wherein the implant is disposed within the delivery sheath in a manner in which a flexible portion of the implant is disposed proximal to the free ends of the gripping members.

**28.** The heart valve repair system of claim **27**, wherein the flexible portion comprises nitinol and fabric.

\* \* \* \* \*